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Atrial fibrillation (AF) and heart failure (HF) have a highly interconnected relationship 
with similar risk factors and shared pathophysiology. They often occur together and are 
associated with increased morbidity and mortality. Unfortunately, the presence of one condition 
has implications for the treatment of the other. Guidelines exist for each disease, however, do not 
provide clarity when treating the conditions together. Due to the complex nature of the combined 
diseases, management requires a systematic and collaborative approach in primary care settings.  
The integrative review seeks to explore the following question, “How can the nurse 
practitioner (NP) best manage HF patients with AF in outpatient settings to help reduce the 
burden on the healthcare system?” A comprehensive search of the literature was undertaken and 
20 articles were selected based on the inclusion criteria. The review findings provide insight into 
the diverse treatment options available to persons living with concomitant AF and HF. From the 
literature, catheter ablation, an invasive and specialized procedure, emerged as a superior 
treatment strategy for patients with combined AF and HF, particularly when compared the 
pharmacotherapy of rate and/or rhythm control. The management of AF in the setting of HF 
requires a collaborative approach between primary care providers (PCP) as well as specialists 
that are able to help manage the population of interest, such as cardiologist and 
electrophysiologists. Recommendations for practice, education, research, and policy have been 
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CHAPTER I: INTRODUCTION AND BACKGROUND 
Heart failure (HF) and atrial fibrillation (AF) are highly interrelated cardiovascular 
disorders. AF often contributes to worsening HF symptoms, and the prevalence of AF parallels 
the severity of HF (Verbrugge & Mullens, 2014). HF is a risk factor, as well as an adverse 
clinical cardiovascular outcome associated with AF. HF and AF often co-exist, predispose each 
other, and share common risk factors including hypertension, diabetes, coronary disease, and 
valvular disease (Staerk et al., 2017). The prevalence of AF in patients with HF ranges from 
13%–27% (Staerk et al., 2017). In a Framingham Heart Study cohort, HF was associated with 
4.5-fold risk of AF in men and 5.9-fold risk in woman (Benjamin et al., 1994), while other 
epidemiological studies demonstrate a 2.67- to 3.37-fold increased risk of AF associated with HF 
(Staerk et al., 2017). Unfortunately, the occurrence of one condition has implications for the 
treatment of the other, and the presence of one condition often hinders treatment for the other 
(Verbrugge & Mullens, 2014). As such, the problem is that as the population ages, the 
prevalence of AF and HF is expected to increase dramatically (Smigorowsky et al., 2017), and 
together they cause greater healthcare burdens. 
 As AF is a “predictor of progression, hospitalization, and death” in HF patients (Andrade 
et al., 2018, p. 1384), attention is needed to develop strategies to best manage individuals with 
concomitant HF and AF in the outpatient setting. These combined conditions also give rise to 
significant financial burdens. Specifically, patients frequently present with exacerbations of AF 
at the emergency department, resulting in AF hospitalizations that cost the Canadian healthcare 
system approximately $815 million annually, which is projected to increase (Smigorowsky et al., 
2017; Verbrugge & Mullens, 2014). Likewise, the individual may face impaired quality of life 
(QoL) and significant personal impacts (Maisel & Stevenson, 2003). As such, the research 
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question to guide the literature review is as follows, “How can the nurse practitioner (NP) best 
manage HF patients with AF in outpatient settings to help reduce the burden on the healthcare 
system?” Due to the predicted inability to meet the future demands for healthcare traditionally 
provided by a physician, NPs are able to focus on individualized patient education and follow up 
based on their patients’ health care needs (Smigorowsky et al., 2017). To reduce the burden on 
the healthcare system, defined therapeutic approaches with supporting evidence require further 
exploration (Kotecha et al., 2014).  
 To contextualize the topic further, I will provide an overview of AF and HF with respect 
to their pathophysiology, epidemiology, and management on their own, in addition to being 
concomitant diseases. Following the background, I will present the methodology of the 
integrative review stages that were undertaken as follows, 1) Development of the research 
question, 2) Preliminary search, 3) Focused search, and 4) Analysis and reporting. After, the 
findings of the integrative literature review will be explored with a focus on the following 
themes, 1) Catheter ablation is superior to medical therapy, 2) Safety considerations, and 3) 
Differing treatment for HF with reduced ejection fraction (HFrEF) and HF with preserved 
ejection fraction (HFpEF). Finally, the findings of the review will be discussed, focusing on the 
relevance towards to primary care providers (PCPs), including NPs. 
Background 
AF is the most common sustained cardiac arrhythmia and is associated with impaired 
functional capacity and reduced QoL. AF is characterized by disorganised electrical impulses 
that lead to a rapid cardiac rhythm and result in the desynchrony of the atrial and ventricular 
chambers of the heart (Andrade et al., 2020; McCance & Huether, 2019). Changes in mechanical 
functioning of the heart, as well as electrical remodeling within the atria, occur in AF. As AF 
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continues, structural changes give rise to electrical changes that generates and propagates ectopic 
foci. These are additional sources of electrical impulses and mechanisms that cause inappropriate 
conductions. As a result, AF begets AF and the longer a person remains in AF, the harder it is to 
restore a normal heart rhythm (McCance & Huether, 2019). 
The prevalence of AF is 1-2% in the general population, and increases significantly in the 
aging population. Specifically, the prevalence is 1% in up to 50 years of age, 4% at 65 years, and 
15% for individuals aged 80 or older (Andrade et al., 2020). The global AF burden is 
underestimated, as about one-third of the total AF population is asymptomatic (Kornej et al., 
2020). AF is associated with increased mortality, and although the arrhythmia does not directly 
cause individuals to be deceased, there are various accompanying comorbidities and 
complications, including HF, myocardial infarction, chronic kidney disease, venous 
thromboembolism, stroke, and dementia (Kornej et al., 2020). Aside from their shared risk 
factors, there are multiple direct causal interactions between AF and its comorbidities, resulting 
in an interdependence in disease development. Specifically, AF is associated with four- to five-
fold increased risk of stroke, and thus the significantly increasing incidence and prevalence 
makes AF a relevant disease in the population with high morbidity, mortality, and significant 
health care costs (Kornej et al., 2020).  
HF and AF are highly interrelated cardiovascular disorders that require multidisciplinary 
collaboration, including utilizing NPs in the primary care and cardiac clinic setting for optimal 
management (Verbrugge & Mullens, 2014). Both disorders occur commonly in developed 
countries and frequently coexist in up to 30% of patients (Prabhu et al., 2017). As the population 
ages, prevalence of AF and HF is expected to increase, contributing to healthcare crisis. The rise 
in healthcare demands are influenced by an overwhelmed healthcare system and financial burden 
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(Smigorowsky et al., 2017). Optimal treatment includes antiarrhythmic drug (AAD) therapy, 
however, the selection of therapies is challenging for the AF and HF population, as there are 
limited medications that may be associated with considerable safety concerns (Piccini & 
Fauchier, 2016). In addition to antiarrhythmic pharmacological management, other rhythm 
control strategies, such as catheter ablation and cardioversion, have also becoming more 
available and their perceived benefit are worth exploring (Verbrugge & Mullens, 2014). 
This literature review will identify strategies to best manage and support patients with AF 
in the presence of HF. There is an opportunity to further understand the synergistic relationship 
of AF and HF, and to explore primary care practices that may improve patient outcomes and 
decrease healthcare costs by reducing complications and rehospitalizations of the combined 
disorders. The research question is as follows, “How can the NP best manage HF patients with 
AF in outpatient settings to help reduce the burden on the healthcare system?” The following 
sections will explore AF and HF through a succinct overview of their individual epidemiology, 
pathophysiology, and management, as well as the combination of the concomitant disorders. 
Atrial Fibrillation 
AF is the most common arrhythmia with an estimated lifetime risk of 22% to 26% for 
individuals between 40 and 55 years of age (Andrade et al., 2020). AF incidence and prevalence 
is increasing globally, as the prevalence of AF has increased three-fold over the last 50 years 
(Kornej et al., 2020). Dysrhythmias, or heart rhythm disorders, are classified according to the site 
of origin of the abnormality, and whether the heart rate is increased or decreased (McCance & 
Huether, 2019; Ritter et al., 2020). AF involves uncoordinated atrial activity, and an irregularly 
irregular rhythm is the hallmark of AF. As such, AF is defined as an atrial arrhythmia. The onset 
of AF requires an initiating trigger and an anatomical substrate, which will be further explored 
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(Zathar et al., 2019). The management is challenging, as the best approach is often not clear and 
treatment must be highly individualized based on the cause (Buttaro et al., 2013). AF may occur 
in the absence of known structural or electrophysiological abnormalities, such as ectopic firing or 
substrate, that changes how the electricity is conducted in the heart. Structural, architectural, and 
electrophysiological atrial abnormalities promote the perpetuation of AF by stabilizing re-entry. 
Once AF is established, tachycardia further induces electrophysiological atrial remodeling 
resulting in persistence of AF (Staerk et al., 2017). 
Pathophysiology 
 Normal heart rhythms are generated by the sinoatrial node and move through the heart's 
conduction system, causing the atrial and ventricular myocardium to contract and relax at a 
regular rate required to maintain adequate circulation (McCance & Huether, 2019). Normal 
automaticity is the cardiac cells’ ability to generate spontaneous activity, and the sinoatrial node 
possess the highest intrinsic rate, thus making it the primary pacemaker of the heart 
(Antzelevitch & Burashnikov, 2011). Cardiac dysrhythmias can be caused by either an abnormal 
rate of impulse generated by the sinoatrial node or by the abnormal conduction of impulses, such 
as a heart block, through the heart's conduction system (McCance & Huether, 2019).  
AF is characterized by high-frequency excitation of the atrium, leading to 
dyssynchronous atrial contraction and irregularity of ventricular excitation (Staerk et al., 
2017). AF involves disturbances that promote ectopic firing and re-entrant mechanisms, 
including ion channel dysfunction, calcium abnormalities, structural remodeling, and autonomic 
neural dysregulation (Andrade et al., 2014). Atrial substrates that promote re-entry are 
characterized by abnormalities of the atrial cardiomyocyte and fibrotic changes (Staerk et al., 
2017). Thus, AF occurs due to diverse mechanisms that cause altered atrial tissue, and 
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consequently create abnormal impulses and propagation of electrical impulses (January et al., 
2014). AF is characterized by rapid excitation of the atrium that results in dyssynchronous atrial 
contraction, as well as irregularity of ventricular excitation. AF may occur without known 
structural or electrophysical abnormalities, however, comorbid conditions have been shown to 
cause structural and histopathological changes (Staerk et al., 2017).  
In AF, cardiac output may decrease significantly due to an impaired atrial systole caused 
by the rapid ventricular rate (tachycardia), and irregular electrical activity in the atria (McCance 
& Heuther, 2019; Stegmann & Hindricks, 2019). The rapid atrial activity, which is between 350 
and 650 beats per minute, and irregularly irregular ventricular response occurs as action 
potentials travel through the atrioventricular node, during which only a fraction of the atrial 
impulses reach the ventricle (Buttaro et al., 2013). Thus, there is no coordinated atrial contraction 
as the electrical impulses in the heart become disorganized (McCance & Huether, 2019; Ritter et 
al., 2020).  
Structural changes and electrical changes in the atria predispose the development and 
maintenance of AF lead to atrial remodeling (Olshansky, 2019). Specifically, the pathological 
features of AF include impaired diastolic dysfunction, causing elevated left ventricular end-
diastolic pressure and increased left atrial pressure and volume (Staerk et al., 2017). Structural 
and electrical changes may occur simultaneously, and can facilitate or create electrical re-entrant 
circuits or triggers that can lead to AF (Olshansky, 2019). Atrial remodeling is associated with 
slower and more varied atrial conduction and increased pulmonary vein firing, and the increased 
left atrial mass supports multiple re-entry circuits (Staerk et al., 2017). Thus, the presence of AF 
results in remodeling of the atrium over time, and thus AF begets AF (Olshansky, 2019). 
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Classification. AF is the most common cardiac rhythm disorder (McCance & Huether, 
2019). AF is a progressive condition that typically begins silently and undiagnosed, and is often 
paroxysmal AF that occurs when episodes of the arrhythmia terminate spontaneously. 
Classifications of AF include paroxysmal, as recurrent self-limiting episodes lasting < seven 
days; persistent, or continuous arrhythmia lasting > seven days and < 12 months; long-standing 
persistent, involving continuous arrhythmias lasting > 12 months; or permanent, as further 
attempts to restore or maintain sinus rhythm should be discontinued as it is not achievable or 
desirable (Golian & Klein, 2021). AF can also develop in individuals without any pathogenic 
conditions or abnormalities (Calvo et al., 2016). For example, lone AF may occur without any 
apparent reason or in response to transient factors, such as increased caffeine, alcohol, or dietary 
intake (Jahangir et al., 2007). Lone AF may resolve spontaneously once the trigger is resolved or 
removed The longer an individual has been in continuous AF, the less likely it is to terminate 
spontaneously, making it more difficult to restore and maintain sinus rhythm (Olshansky, 2019). 
Clinical Manifestations. Although symptoms of AF are nonspecific and often not 
present, they may include palpitations, fatigue, dizziness, light headedness, and dyspnea (Buttaro 
et al., 2013). On an electrocardiogram, AF appears as a normal P-wave replaced by fibrillatory 
F-waves, which produces a wavy baseline (Buttaro et al., 2013). Lone AF is often asymptomatic, 
however it may be captured by chance (Calvo et al., 2016). AF can also be associated with an 
increased risk of stroke and transient ischemic attack, which is in turn linked to long-term 
disability and mortality (Staerk et al., 2017). In some patients, AF may be asymptomatic and the 
first indication of AF may occur following presentation with stroke or transient ischaemic attack 




AF is the most common sustained arrhythmia with a prevalence of one million 
Canadians, with a substantial economic burden attributed to direct costs associated with 
hospitalization and the provision of acute care (Andrade et al., 2020). As well, advanced age, 
male sex, and European ancestry are prominent AF risk factors, which are non modifiable. Other 
modifiable risk factors that predispose individuals to AF include hypertension, sedentary 
lifestyle, tobacco, obesity, alcohol, diabetes mellitus, and obstructive sleep apnea (Staerk et al., 
2017). 
Prevalent and Incidence. AF is the most common cardiac rhythm disorder in older 
adults with a prevalence of 15 % for individuals aged 80 or older (Andrade et al., 2020). In 
developed countries, AF is present in 3-6% of those admitted to hospitals with acute conditions 
(McCance & Huether, 2019). The approximate global number of individuals with AF in 2010 
was 33.5 million; specifically, 20.9 million men and 12.6 million women (Chugh et al., 2014). In 
the United States of America (USA), three to six million people have AF, and the numbers are 
projected to reach six to 16 million by 2050 (Kornej et al., 2020). In Europe, prevalent AF in 
2010 was almost nine million among individuals older than 55 years, and is expected to reach 14 
million by 2060 (Kornej et al., 2020). As well, it was estimated that by 2050, AF will be 
diagnosed in approximately 72 million individuals in Asia (McCance & Huether, 2019). The rise 
in prevalence and incidence of AF is largely due to an aging population, as the incidence doubles 
with each decade of life and thus the rate of AF dramatically increases with advancing age 
(Piccini et al., 2013). Other factors may include rising levels of chronic disease and obesity 
(Staerk et al., 2017).   
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Cost and Burden on the Healthcare System. AF creates a significant problem for 
healthcare systems worldwide, as estimates suggest that AF accounts for 1% of the National 
Health Service budget in the United Kingdom and $16-26 billion of annual USA expenses 
(Chugh et al., 2014). In Canada, the annual direct cost of AF care in 2020 was $956 million, 
which includes $66 million for emergency department visits for primary diagnosis of AF and $20 
million with comorbid AF; $204 million for hospitalization with the primary diagnosis of AF and 
$634 million with comorbid AF; and $32 million for day procedures related to AF (Andrade et 
al., 2020). Thus, AF’s impact on healthcare expenditures is majorly due to hospitalizations 
(Chugh et al., 2013). For example, in a study by Delaney et al. (2018), caring for patients with 
AF was deemed costly in the USA healthcare system, majorly due to increase in prevalence of 
HF, population longevity with cardiovascular disorders, and aging of the population. When 
comparing older individuals with and without AF and a follow-up period of 1 year, the estimated 
incremental hospital and clinical Medicare costs for patients with AF was $18,601. 
Risk Factors. The risk factors of AF generally induce structural and electric remodeling 
of the atria, and there are a variety of risk factors for developing AF (McCance & Huether, 
2019). Cardiovascular disease risk factors, including advanced age, male sex, alcohol 
consumption, smoking, and diabetes, contribute to the development of AF (McCance & Huether, 
2019). Age is one of the most significant predictors of incident AF due to structural and 
electrical remodelling. Sex is also a strong predictor of AF, as males have a 1.5-fold increased 
risk for developing AF. Additionally, diabetes is associated with a 1.5 times increased risk due to 
structural, electrical, and autonomic remodelling. However, dyslipidemia has an unclear 
association with AF (Andrade et al., 2020).  
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Lifestyle factors, such as tobacco use, alcohol consumption, and a sedentary lifestyle are 
associated with an increased risk of developing AF (Andrade et al., 2020). Sedentary lifestyle is 
linked to autonomic dysfunction and elevated sympathetic tone, thus enhancing 
afterdepolarization triggering and AF susceptibility. Paradoxically, endurance athletes are also at 
risk of AF, as they have increased vagal tone which may shorten and increase pulmonary vein 
firing, as well as cause progressive cardiac remodeling, and atrial enlargement and fibrosis 
(Staerk et al., 2017). Obesity is also a risk factor, as body mass index (BMI) and AF have a 
linear relationship with AF incidence increasing 3-7% of unit increase in BMI (Andrade et al., 
2020). Obstructive sleep apnea is common in obese individuals and has been associated with 
sedentary lifestyle and systematic inflammation causing atrial remodelling. Sleep apnea is highly 
prevalent in those with AF, with a rate that is twice the general population (Staerk et al., 2017).  
Hypertension is a strong independent risk factor, as it causes neurohormonal activation, 
structural remodelling and thus atrial fibrosis, as well as electrical remodelling causing 
conduction disturbances (Andrade et al., 2020). Additionally, valvular heart disease has been 
implicated with a 1.8- to 3.4-fold increased risk for AF due to structural remodelling. For the 
same reason, AF is associated with an increased complexity of rheumatic heart disease (Andrade 
et al., 2020). Moreover, AF increases the severity of cardiomyopathy, or HF, symptoms. HF 
causes structural and electrical remodelling, as well as neurohormonal activation due to 
increased sympathetic activity and impairment of vagal tone (Andrade et al., 2020). The 
prevalence of AF in patients with HF ranges from 13% to 27%, and the prevalence rises with 
increased New York Heart Association (NYHA) functional class (Staerk et al., 2017). As well, 
AF increases with hyperthyroidism due to neurohormonal activation, structural and electrical 
remodelling, and promotion of the pulmonary vein automaticity (Andrade et al., 2020). Lastly, 
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AF occurs more often in those with a family history of AF in a first-degree relative, specifically 
due to cardiac ion channel alterations, alterations in cellular coupling, or increased susceptibility 
to AF (Andrade et al., 2020). 
AF is the most common sustained rhythm and is associated with a substantial economic 
burden (Andrade et al., 2020). AF ranges from isolated electrophysiological disorder, or a 
manifestation of a cardiac or noncardiac pathology. As individuals age, the contribution of 
abnormal substrate predominates, including nonmodifiable risk factors related to age, sex, and 
genetically determined factors, modifiable risk factors related to reversible risk factors, as well as 
substrate induced by the AF episodes themselves. Thus, strategies targeting modifiable 
cardiovascular risk factors and relevant comorbid conditions improve survival rates (Andrade et 
al, 2020). 
Management 
 The risk of developing AF increases with the severity and presence of modifiable 
cardiovascular risk factors, including hypertension, diabetes mellitus, and obesity (Staerk et al., 
2017). Due to the complex and multifaceted nature of AF, a systematic approach of AF 
management is required. The initial management of AF can be provided by PCPs, in addition to 
the support of cardiologists, cardiac clinic NPs, and others engaged in cardiac care, to guide 
management decisions for patients who develop difficulties during therapy. There are 
multidisciplinary clinics that exist with a focus on AF care, which includes facilitating patient 
and provider education, advanced treatment options, and evidence-based care centred on chronic 
disease management (Andrade et al, 2020).  
Treatment strategies include achieving a normal heart rate, restoring normal rhythm, and 
reducing the risk of stroke (McCance & Huether, 2019). Considerations when deciding the type 
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of management includes the efficacy and safety profile of the medication, as well as the patient’s 
tolerability and preference (Andrade et al., 2020). As well, the causes of AF should be 
considered, as it is important to determine whether treatment aims at attempting to restore and 
maintain sinus rhythm through rhythm control, or manage ventricular rate control. Factors that 
contribute to the decision include duration of the AF and left atrial size, as left atrial enlargement 
and prolonged duration of AF can reduce the ability to be successful in maintaining normal sinus 
rhythm. Additionally, restoration and maintenance of sinus rhythm aids in symptomatic relief, 
prevention of embolism, and prevention of cardiomyopathy (Buttaro et al., 2013). 
Pharmacological interventions, such as anticoagulation, rhythm control, and rate control, and 
nonpharmacological interventions, such as catheter ablation  and cardioversion, will be briefly 
discussed.  
Pharmacological Interventions. The primary decision of medical management in AF is 
whether to choose rate control, thus leaving atrial arrhythmia as the permanent rhythm, or 
rhythm control, thus actively pursuing a sinus rhythm (Ritter et al., 2020). There is also a goal 
stroke prevention in the AF population (McCance & Huether, 2019). 
Rhythm Control. Rhythm control is preferred for individuals with a diagnosis of AF 
within a year. Long-term rhythm control is also recommended in patients with AF who remain 
symptomatic with rate control, or where rate control therapy is unlikely to control symptoms. 
Rhythm control may not completely suppress AF, thus the focus is on symptomatic management. 
Commonly used AADs include propafenone, flecainide, sotalol, and amiodarone. The initial 
choice is driven by safety and tolerability of the patient. Of the available AADs, only 
amiodarone and dofetilide are recommended in patients with left ventricular dysfunction and/or 
clinical HF. Amiodarone is the most effective AAD, however the potency is at most 60% at one 
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year. Dofetilide therapy is less effective, and its initiation requires a three-day hospitalization due 
to its potential to prolong the QT interval and can cause torsades de pointes, a life threatening 
arrhythmia (Thihalolipavan & Morin, 2015).   
AF triggers and modifies AF substrates (McCance & Huether, 2019). Thus, rhythm 
control should be pursued in patients with more than minimal symptoms, in asymptomatic young 
patients, and in those with possible tachycardia-related cardiomyopathy. There are many 
medications that may be used to control AF, however amiodarone is the most commonly used 
drug (Ritter et al., 2020). Amiodarone is a class III AAD with complex pharmacological 
properties, including a long half-life. Long-term use increases the risk for extracardiac toxicities 
affecting the skin, thyroid, pulmonary, liver, and neurological systems (Andrade et al., 2020). 
Thus, while amiodarone is more effective than sotalol or propafenone for the prevention of 
recurrences of AF, it is associated with significant adverse and side effects. As a result, 
amiodarone can be poorly tolerated and may be discontinued, and particularly stopping the drug 
in up to 18% of patients (Ritter et al., 2020). As such, amiodarone should not be considered as 
first-line therapy (Andrade et al., 2020). 
Rate Control. Long-term rate control involves agents with negative chronotropic 
properties, including beta blockers (BB), including metoprolol or bisoprolol, and 
nondihydropyridine calcium chancel blockers (ND-CCB), such as verapamil and diltiazem. 
These drugs act to modulate the activity of the sinoatrial and atrioventricular nodes, and are 
recommended for initial control of heart rate (McCance & Huether, 2019; Ritter et al., 2020). 
There are many different drugs that may be used, each with their own mechanisms of action, and 
each drug is chosen based on the individualized patient’s needs. For example, patients without 
significant left ventricular dysfunction, BBs and ND-CCBs are first line medications (Andrade et 
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al., 2020). In patients with significantly impaired left ventricular systolic function, BBs are the 
first line for rate control (Andrade et al., 2020). Digoxin may also be used, which increases the 
stability of cell membranes and should be considered only when response to first-line agents is 
inadequate, since it is not very effective and has concerns of increased mortality (Ritter et al., 
2020). Although amiodarone is a class III AAD, it is also a multichannel blocker and a 
nonselective BB. Thus, patients that are critically ill, or with side effects from first-line agents, 
may benefit from amiodarone for rate control therapy (Andrade et al., 2020). 
Stroke Prevention. In AF, the ineffective blood pumping raises the likelihood of 
coagulation and thrombosis, causing an increased risk of stroke and often require preventative 
oral anticoagulant therapy (McCance & Huether, 2019). Warfarin and acetylsalicylic acid (ASA) 
have been used for many years in this population, although ASA is less effective than warfarin 
AF (Ritter et al., 2020). Additionally, apixaban, dabigatran, edoxaban and rivaroxaban have been 
approved for prevention of systemic embolism in patients with AF, which are the four direct oral 
anticoagulants currently approved for use in Canada (Andrade et al., 2020; Ritter et al., 2020). 
Additionally, utilizing a rhythm control strategy for patients newly diagnosed with AF is 
associated with reduced cardiovascular death and reduced rates of stroke. It is also recommended 
that patients with AF should undergo annual assessment of their risk of stroke and systemic 
embolism, regardless of their type of AF (Andrade et al., 2020). Stroke prevention remains a 
central focus for those living with AF. 
Nonpharmacological Interventions. If medical therapy does not achieve the desired 
results, cardiac interventions, such as catheter ablation, may be a feasible option. Ablation of AF 
may also be the preferred therapy for patients with recurrent AF that desire long-term rhythm 
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control (Andrade et al., 2020). As well, breakthrough episodes of AF can be terminated by either 
electrical or chemical cardioversion when significantly compromised (Ritter et al., 2020). 
Catheter Ablation. Catheter ablation is the delivery of radiofrequency or cryothermal 
energy by targeting tissue injury in the heart, with a goal of preventing recurrence of the 
arrhythmia (Golian & Klein, 2021). Pulmonary veins have been shown to be the main trigger 
source for AF. Thus, pulmonary vein isolation (PVI) is the primary treatment for symptomatic 
patients with paroxysmal and persistent drug-refractory AF, however AF recurrence is common 
(Rottner et al., 2020). Although radiofrequency-based PVI has been the mainstay treatment, 
novel ablation techniques, particularly cryoballoon, has emerged as the most commonly used 
alternative AF ablation tool (Rottner et al., 2020). Catheter ablation is often not an absolute cure 
for AF, but can significantly reduce the arrhythmia burden (Ritter al., 2020). 
The success rate for ablation of AF is high with a low rate of complications, varying from 
50–80% depending on technique, AF subtype, and the extent of structural heart disease (Ritter 
al., 2020). A quantitative, multi-centered, and randomized control trial by Di Biase et al. (2016) 
demonstrated that the success rate of catheter ablation after a single procedure ranged from 29% 
to 61% in patients with persistent AF, as well as it was associated with decreased hospitalizations 
and mortality. Catheter ablation offers an opportunity to achieve sinus rhythm without the 
adverse effects of AAD therapy. Treatment of catheter ablation for patients with HF should be 
individualized by weighing the potential long-term benefits of successful ablation against the 
risks of intra-procedural complications (Liang & Callans, 2018). Thus, if rate or rhythm control 
cannot be achieved with medication, catheter ablation can be considered (Ritter et al., 2020); 
particularly if patients are symptomatic and have failed or do not wish to remain on AAD 
therapy long term (Golian & Klein, 2021). 
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Cardioversion. AF that produces hemodynamic compromise, acute coronary syndrome, 
or pulmonary edema, and is resistant to prompt medical management, should be terminated 
electrically (Andrade et al., 2020; Golian & Klein, 2021). The initial success rate of 
cardioversion for AF is 70–90%, however approximately 20% of patients will remain in sinus 
rhythm after a year (Golian & Klein, 2021). As such, cardioversion is recommended in 
hemodynamically unstable and symptomatic AF individuals that require restoration of sinus 
rhythm from a tachycardic heart rate (Stegmann & Hinkdricks, 2019). Cardioversion can also be 
a useful adjunctive measure in patients with breakthrough episodes of AF (Golian & Klein, 
2021). Specifically, AF breakthrough episodes can be terminated by either electrical or chemical 
cardioversion. Options for chemical cardioversion include oral flecainide, or propafenone, in 
addition to intravenous amiodarone, ibutilide, or procainamide (Ritter et al., 2020). 
When AF is not responsive to medical therapy, nonpharmacological interventions may be 
necessary (Golian & Klein, 2021). Although AF ablation is often not a complete cure for AF, it 
significantly reduces the arrhythmia burden. Thus, it is a recommended option for patients that 
would like to avoid long term AAD therapy (Golian & Klein, 2021). 
Heart Failure 
HF is a complex clinical syndrome with signs and symptoms of volume excess that range 
from mild dyspnea on exertion caused by fluid retention, to cardiogenic shock and lethal 
arrhythmias (Buttaro et al., 2013). HF affects approximately 37.7 million people worldwide (Hu 
et al., 2021). HF is the result of cardiac dysfunction, or the “inability of the heart to meet the 
body’s metabolic demands” (Buttaro et al., 2013, p. 537), resulting in reduced longevity. HF is 
caused by a structural or functional cardiac disorder, which impairs the ventricles from filling or 
ejecting properly (Buttaro et al., 2013). HF does not occur independently, as it is caused by an 
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underlying cardiac defect and has an increased prevalence with the aging population (Andrade et 
al., 2020). The disease is one of the most common, costly, debilitating, and morbid conditions in 
primary and secondary care (McMurray & Pfeffer, 2005). An increase in natriuretic peptide 
concentrations, specifically B type natriuretic peptide, is a hallmark of HF (Mosterd & Hoes, 
2007). Patients with HF often require frequent hospitalizations, in addition to experiencing a 
significantly reduced QoL and exercise intolerance (De Denus & White, 2019).  
Pathophysiology 
HF is characterized by impaired LV function and reduced LV reserve, characterized by 
signs and symptoms due to an excess amount of volume (De Denus & White, 2019). Generally 
in HF, the heart is unable to generate a cardiac output to adequately perfuse tissues or causes 
increased diastolic filling pressure of the left ventricle. Cardiac output depends on the heart rate 
and stroke volume, and stroke volume is influenced by preload, afterload, and contractility. 
Preload is the degree of myocardial fiber stretch at the end of ventricular filling. Afterload is the 
amount of left ventricular wall tension that develops during systole, determined by the size of the 
ventricular chamber and the dynamic vascular resistance which the heart must contract against 
(Buttaro et al., 2013). Lastly, contractility of the myocardium is a change in tension at a given 
resting fiber length, or the ability of the heart muscle to shorten (McCance & Huether, 2019). 
Thus, the abnormal heart function causes signs and symptoms of reduced cardiac output and/or 
pulmonary or systemic congestion at rest or during exercise (Ezekowitz et al., 2017). 
Classification. The American College of Cardiology (ACC) and the American Heart 
Association (AHA) have created an ACC/AHA HF Stages system to grade HF by stage, 
including patients at risk for the development of HF (stage A) and those with end-stage, 
advanced disease (stage D) (Buttaro et al., 2013). Complementary to the ACC/AHA staging, the 
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NYHA classification is used to classify severity of HF and indicate prognosis to help guide 
management. Severity ranges from asymptomatic (NYHA I), which is well managed patients 
without symptoms, to mild (NYHA II), which is slight limitation in physical activity, to 
moderate (NYHA III), which is symptoms while walking, to severe (NYHA IV), which is 
breathless at rest (Buttaro et al., 2013; Mosterd & Hoes, 2007).  
HF a clinical syndrome with signs or symptoms caused by a structural and/or functional 
cardiac abnormalities (Gibson et al., 2021), and is categorized on the basis of left ventricular 
ejection fraction (LVEF) (Ezekowitz et al., 2017). Specifically, HFrEF is characterized by a 
symptomatic decrease in the EF of ≤ 40%, in addition to cardiac output (Ezekowitz et al., 2017; 
Gibson et al., 2021). HF with mildly reduced ejection fraction is considered symptomatic HF 
with LVEF between 41 and 49%. HFpEF occurs with symptoms when the LVEF is ≥ 50% 
(Ezekowitz et al., 2017; Gibson et al., 2021). A new classification of HF is HF with improved 
ejection fraction, which is defined as symptomatic HF with a baseline of LVEF ≤ 40%, a ≥ 10-
point increase from baseline LVEF, and a second measurement of LVEF > 40%. As cardiac care 
is a rapidly evolving field, new classifications and diagnostic guidelines are continually being 
developed. Classifying HF by stage allows PCPs the opportunity to communicate with patients in 
a more practical manner and provide explanations to allow for greater shared decision-making 
(Gibson et al., 2021). 
HFrEF. HFrEF is defined as a reduction in the ventricle’s contractility leading to an 
inadequate cardiac output to perfuse vital tissues (De Denus & White, 2019). The three 
determinants of ventricular function, which are preload, contractility, and afterload, are altered. 
Increased preload occurs because the heart ejects insufficiently, resulting in an increased volume 
of blood that remains in the ventricular chambers. The result is increased left ventricular end-
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systolic volume, which leads to distention of the ventricles and increased interventricular 
pressure at the onset of diastole. Normally, the heart is able to withstand a small increase of 
volume and pressure, while continuing to maintain cardiac output. Inversely, in HF the 
myocardial fibers are excessively overloaded and stretched beyond the limits of a normal reflex-
increased force of contraction. The result is left ventricular remodelling with dilation and 
impaired contractility, and activations of the sympathetic and renin-angiotensin-aldosterone 
system (RAAS) (Buttaro et al., 2013).  
Decreased contractility causes stroke volume to fall, and left ventricular end diastolic 
volume increases, causing dilation of the heart and increased preload. Increases in left ventricular 
end diastolic volume can temporarily improve cardiac output, however as preload continues to 
rise, the myocardium stretches and eventually leads to dysfunction of the sarcomeres and 
decreased contractility (McCance & Huether, 2019). Therefore, a decrease in myocardial 
contractility, reduction in EF, and a reduction in stroke volume and cardiac output occurs. 
Specifically, systolic blood pressure is closely related to afterload, and thus is a relevant clinical 
indicator of myocardial load or afterload, and an afterload-dependent measure of contractility 
(Buttaro et al., 2013). Contractility is reduced by diseases that disrupt myocyte activity, such as 
myocardial infarction, myocarditis, and cardiomyopathies, which contribute to inflammatory, 
immune, and neurohormonal changes that mediate ventricular remodeling. Ventricular 
remodelling results in disruption of normal myocardial extracellular structure with resultant 
dilation of the myocardium and causes progressive myocyte contractile dysfunction (McCance & 
Huether, 2019). A prolonged increase in preload and afterload are implicated in HF, as they 
contribute to ventricular dysfunction and enlargement, decreased myocardial contractility, 
reduction in EF, and thus a reduced stroke volume and cardiac output (Buttaro et al., 2013).  
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A cardiac output that is insufficient to meet metabolic demands leads to an increase in 
fluid volume due to increasing venous pressure, therefore leads to increased capillary pressure. 
There is an increase formation of tissue fluid caused by reduced renal blood flow activates the 
RAAS, causing sodium and water retention, which acts to increase pulmonary vascular 
remodeling and plasma volume, thus increasing afterload and preload (McCance & Huether, 
2019; Ritter et al., 2020). Specifically, the reduced cardiac output causes decreased renal 
perfusion and trigger activation of the RAAS system, which increases peripheral vascular 
resistance and plasma volume and further contributes to increased preload and afterload. 
Additionally, the baroreceptors in the central circulation detect the decrease in perfusion and 
stimulate the sympathetic nervous system to cause increased vasoconstriction, causing the 
hypothalamus to produce antidiuretic hormone. Thus, increased preload, increased afterload, and 
decreasing contractility also contributes to the progressive worsening of HF (McCance & 
Huether, 2019). 
HFpEF. HFpEF is defined as impairment of the ventricular filling and relaxation, 
causing pulmonary congestion despite a normal stroke volume and cardiac output (Buttaro et al., 
2013; De Denus & White, 2019; McCance & Huether, 2019). It is caused by increased 
ventricular stiffness and reduced compliance of the left ventricle, causing a rise in cardiac filling 
pressures during ventricular relaxation. The distensibility of the left ventricular is reduced for all 
or part of diastole, causing filling pressures to increase for maintenance of a constant ventricular 
volume (Buttaro et al., 2013). The failure of a normal rise in cardiac output during periods of 
exertion causes dyspnea, or difficult breathing, which is a classic symptom of HF. As such, the 
heart will attempt to compensate for the impaired distensibility through left atrial contracting, 




HF is a deadly and disabling disease with signs and symptoms caused by cardiac 
dysfunction (Mosterd & Hoes, 2007), which increases patients requiring hospital admission 
(McMurray & Pfeffer, 2005). Specifically, 30 – 40% of patients die within a year of diagnosis 
and 60 – 70% die within five years, majorly due to worsening heart failure or suddenly. As such, 
there is a one in five risk for developing HF for a person aged 40 years, as well as a one in three 
chance of dying within a year of diagnosis (McMurray & Pfeffer, 2005). 
Prevalent and Incidence. HF is considered a global epidemic disease that affects 
approximately 1% to 2% of adult population in the western world, and incidence approaches five 
to 10 per 1000 persons annually (Mosterd & Hoes, 2007). Specifically, 5.7 million Americans 
older than 20 years of age have HF, causing one in nine deaths in the USA (McCance & Huether, 
2019), and the prevalence and incidence increase progressively over the age of 50 years 
(Mosterd & Hoes, 2007). HF majorly affects the elderly, as 6-10% of people over the age of 65 
years are diagnosed with the disease (McMurray & Pfeffer, 2005), and 80% of HF-related 
hospitalizations and 90% of HF-related deaths occur among patients aged 65 years or older.  
In a study by Lloyd-Jones et al. (2002), the incidence of HF doubled over each 
consecutive decade of life, rising more with age in women than in men. The annual incidence in 
men increased from two per 1000 at age 35 to 64 years to 12 per 1000 at age 65 to 94 years, and 
the lifetime likelihood of developing HF is approximately 20% for individuals above the age of 
40. A further rise in HF cases is expected due to a higher proportion of elderly people and better 
survival rates of patients with risk factors for developing HF (Lesyuk et al., 2018). 
Cost and Burden on the Healthcare System. HF is a significant and increasingly 
prevalent medical and economic problem worldwide, as it encompasses 1-2% of the healthcare 
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budget. The prevalence of HF has increased over the past decades and is expected to continue to 
raise due to the higher proportion of elderly in the western societies (Lesyuk et al., 2018). The 
annual mortality rate of HF is 6-25% depending on the severity of symptoms (De Denus & 
White, 2019). The Meta-Analysis Global Group in Chronic HF by Pocock et al. (2012) discusses 
the development of a prognostic model in HF patients that readily quantifies individual patient 
mortality risk. The results showed that for 39,372 patients with HF from 30 studies, 40.2% of 
patients died during a median follow-up of 2.5 years. The study showed that the patient’s overall 
prognosis is variable, however, the overall risk profile helps identify patients in need of intensive 
monitoring and therapy, as well as the need of new therapies. 
Patients diagnosed with HF have a poor prognosis and high hospitalization rates 
(Heidenreich et al., 2013). In a literature review by Cook et al. (2012), the overall economic cost 
of HF in 2012 was approximately $108 billion a year, with 60% accounting for direct costs and 
40% accounting for indirect costs. The USA is attributed as the biggest contributor to the global 
HF costs, as it accounts for 28.4% of the total global HF expenditure. A policy statement from 
the American Heart Association by Heidenreich et al. (2013) states that costs related to the 
treatment of HF is 2-3% of the total expenditure of healthcare systems in developed countries, 
and are projected to increase by more than 200% in the next 20 years due to the aging 
population. By 2030, more than eight million people in the USA will develop HF. Between 2012 
and 2030, total direct medical costs of HF are projected to increase from $21 billion to $53 
billion. Total costs, including indirect costs for HF, are estimated to increase from $31 billion in 
2012 to $70 billion in 2030. If all costs of cardiac care for HF patients are attributable to HF and 
not attributed to comorbid conditions, the 2030 projected cost estimates of treating patients with 
HF will be three-fold higher, or $160 billion in direct costs. 
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Risk Factors. The etiology of HF is divided into three categories: 1) Anatomic or 
functional abnormalities of the coronary vessels, myocardium, or cardiac vales; 2) 
Neurohormonal overexpression of biologically active molecules, activating the adrenergic 
nervous system and RAAS; and 3) Extracardiac factors, creating an increased demand on the 
cardiovascular system (Buttaro et al., 2013). Many conditions are able to cause HF, such as age, 
smoking, diabetes, renal failure, coronary artery disease, hypertension, cardiomyopathies, 
valvular and congenital heart disease, arrhythmias, pericardial disease, myocarditis, pulmonary 
hypertension, and cardiotoxic substances (McCance & Huether, 2019; Mosterd & Hoes, 2007). 
As well, obesity doubles the risk of HF, which is increasingly prevalent in western societies 
(Mosterd & Hoes, 2007). However, ischemic heart disease and hypertension are the most 
significant predisposing risk factors, as 75% of HF cases occur in persons with hypertension 
(McCance & Huether, 2019). Moreover, coronary artery disease is the most common cause of 
HFrEF, whereas hypertension, AF, and diabetes are common causes of diastolic dysfunction 
(Buttaro et al., 2013). Diabetes can produce HF independently of coronary artery disease by 
causing a diabetic cardiomyopathy through promoting the development of myocardial fibrosis 
and diastolic dysfunction, autonomic dysfunction, and worsened renal and endothelial function. 
The incidence of HF was two- and four-fold higher in patients with diabetes than in those 
without. Approximately 12% of patients with diabetes have HF, and older than the age of 64 
years, the prevalence increases to 22% (Ezekowitz et al., 2017). 
Management 
The goal of therapy for patients diagnosed with HF includes treating modifiable risk 
factors, avoiding exacerbating factors, preventing disease progression, improving symptoms, 
improving exercise tolerance and QoL, and reducing morbidity and mortality (De Denus & 
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White, 2019). The prognosis is now much improved compared with previous eras, however 
patients with advanced HF who fail to respond to disease modifying therapy have a poor 
prognosis and impaired QoL. Thus, early referral for palliative care support might be considered 
during the advanced stages of HF (Fine et al., 2020). As well, treatment strategies for HF 
involves managing common risk factors for the development of HF, such as smoking, obesity, 
alcohol use, sedentary behaviour, hypertension, diabetes, and dyslipidemia, which will be briefly 
addressed below (Ezekowitz et al., 2017).  
Pharmacological Interventions. HF requires sufficient diagnostic testing in order to 
determine the specific cause. After a diagnosis is made, the goals of therapy are to relieve 
congestion, treat specific reversible causes, and then management of the residual heart failure. It 
is important to note that HF caused by diastolic dysfunction must be differentiated from that 
caused by systolic dysfunction, as treatment options differ (Buttaro et al., 2013). Medications are 
required to address symptoms and optimize cardiac function in HF, and as well as manage other 
comorbidities. However, side effects may occur due to the polypharmacy nature of HF 
management (Ezekowitz et al., 2017).  
HFrEF. For patients diagnosed with HFrEF, therapy incorporates angiotensin receptor-
neprilysin inhibitor (ARNI) as first-line therapy or after angiotensin converting enzyme inhibitor 
(ACEI)/angiotensin receptor blocker (ARB) titration, as well as BBs, mineralocorticoid receptor 
antagonists (MRA), and sodium glucose transport 2 inhibitors (McDonald et al., 2021). 
Sacubitril-valsartan is the only available ARNI in Canada, and dosing and titration is 
individualized (McDonald et al., 2021). ARBs differ pharmacologically from ACEIs, however, 
act similarly to ACE inhibitors. ACEIs have greater evidence than ARBs, reducing 
cardiovascular morbidity and mortality compared with placebo in hypertension (Ritter et al., 
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2020). BBs have cardio-depressant effects and decrease cardiac rate and force, whereas ACEIs 
cause vasodilation and reduce cardiac load as well as arterial pressure (Ritter et al., 2020).  
Diuretics are used to control signs and symptoms of hypervolemia and maintain 
euvolemia. Thiazide diuretics can be used in patients with minimal fluid retention, however loop 
diuretics, such as furosemide, are often required to control congestion and peripheral edema (De 
Denus & White, 2019; Ezekowitz et al., 2017). Other therapies that improve HF outcomes 
include sinus node inhibitors, soluble guanylate cyclase stimulators, hydralazine/nitrates in 
combination, and/or digoxin (McDonald et al., 2021). Digoxin causes cardiac slowing and 
reduces the ventricular rate of conduction, as well as increases the force of cardiac contraction. 
Digoxin is used in HF for patients who remain symptomatic, despite use of diuretics and ACEIs 
(Ritter et al., 2020). 
HFpEF. For patients diagnosed with HFpEF, therapy involves controlling risk factors, 
such as hypertension, diabetes mellitus, ventricular rate, regulatory volume status, and 
decreasing heart rate to improve filling time. Although chronic use of RAAS modulators, such as 
ACEIs, does not reduce the risk of mortality in this population, these agents should be used to 
treat hypertension, left ventricular hypertrophy, nephropathy or coronary artery disease due to 
their efficacy and end-organ protection. Additionally, MRAs are recommended with 
symptomatic patients, serum potassium < 5 mmol/L and glomerular filtration rate ≥ 30 mL/min, 
however close monitoring of potassium and creatinine is required. BBs, such as metoprolol, are 
recommended for patients with coronary artery disease, previous myocardial infarction, 
hypertension, or AF due to their ability to control ventricular rate in patients. Diuretics, 
furosemide, are considered to optimize volume status. Calcium channel blockers (CCB), such as 
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verapamil or diltiazem, are considered to control the ventricular rate for those with angina or 
unable to tolerate BBs (De Denus & White, 2019). 
Comorbidities. HF guidelines state that dyslipidemia should be treated in patients with 
evidence of vascular disease or diabetes with lipid lowering drugs, particularly statins 
(Ezekowitz et al., 2017). The benefit of statins in the primary and secondary prevention of 
coronary artery disease is well established, however the benefits of statins in patients with HF is 
limited (Denus & White, 2019). As well, an intensive glycemic control strategy is not 
recommended for all patients with diabetes, as they should be assessed for their optimal 
glycemic target for the prevention of macrovascular events or HF. Metformin is still considered 
first-line pharmacological therapy for type two diabetes, as it is effective with a known safety 
profile, and is well tolerated in patients with HF. SGLT-2inhibitors, such as dapagliflozin and 
empagliflozin, benefit patients with HF, with or without diabetes (McDonald et al., 2021). 
Nonpharmacological Interventions. Nonpharmacological management involves a 
variety of approaches. Clinical assessment should include an assessment of symptoms, volume 
assessment, and monitoring of vital signs, renal function, electrolytes, and creatinine (Ezekowitz 
et al., 2017. 
Lifestyle Modification. Moderate, regular exercise as tolerated is recommended to 
improve exercise capacity, symptoms, and QoL, and has shown to decrease hospital admissions 
(Ezekowitz et al., 2017; Ritter et al., 2020). Sedentary lifestyle and obesity are risk factors for the 
development of HF, as well as exacerbation of HF (Ezekowitz et al., 2017. Additionally, alcohol 
reduction is advised for all patients with HF, or complete avoidance if it is responsible or 
contributes to the syndrome due to the dose dependent effect and individual susceptibility to the 
deleterious effects of alcohol. No more than one alcoholic drink per day is recommended in all 
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patients, and avoidance is recommended in alcoholic cardiomyopathy (Ezekowitz et al., 2017; 
De Denus & White, 2019; Ritter et al., 2020).  Importantly, smoking has been linked to the 
progression of cardiovascular disease, and thus smoking cessation is encouraged. Nicotine 
replacement therapy or other smoking cessation therapies are recommended (Ezekowitz et al., 
2017). As well, reduced dietary intake of sodium is associated with improved clinical outcome, 
thus patients with HF should restrict  their dietary salt intake between 2 to 3 g per day 
(Ezekowitz et al., 2017). 
Fluid Restriction. Fluid intake should be restricted to 2 L per day for patients with fluid 
retention or congestion not controlled by diuretics. To monitor fluid retention and congestion, 
daily morning weight should be taken for patients with HF and fluid retention or congestion, or 
with significant renal dysfunction. Any rapid weight gain >1.5 or 2 kg warrants a rapid medical 
visit (Ezekowitz et al., 2017; De Denus & White, 2019; Ritter et al., 2020).  
Devices. There are multiple devices considered for HF patients based on their clinical 
status. Due to their cost, devices are typically reserved for patients without significant 
comorbidities that are expected to limit their survival. Implantable cardioverted defibrillators 
(ICD) are recommended for NYHA class II-III and LVEF ≤35%, or NYHA class I and LVEF ≤ 
30% (De Denus & White, 2.019). The primary indication for ICD implantation in patients with 
HF is the prevention of sudden death. ICD devices can also act as pacemakers and treat 
ventricular arrythmias by delivering shocks via the coils on the lead and the generator. The ICD 
is placed subcutaneously in the pectoral region where pacemakers are implanted, and the leads 
are placed in the endocardium of the atria and the ventricle (Muthumala, 2017). Patients with 
significant comorbidities may not benefit from an ICD for treatment of the arrythmia, and thus 
resynchronization may be considered if they meet certain criteria (Muthumala, 2017).  
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Cardiac resynchronization therapy (CRT) is widely accepted as a significant component 
of standard HF therapy. In most patients, CRT reduces clinical symptoms, improves exercise 
tolerance, and reverses cardiac remodeling (Hu et al., 2021). CRT is appropriate for patients with 
NYHA class II, III, and ambulatory NYHA class IV. The procedure is more complicated than for 
an ICD, as there are right atrial and right ventricular leads as well as a pacing lead placed in a 
branch of the coronary sinus (Muthumala, 2017).  
Left ventricular assist devices are used at end-stage heart failure and can be considered as 
a bridge to cardiac transplantation. Also, continuous positive airway pressure is considered in 
patients with obstructive sleep apnea due to HF (De Denus & White, 2019). Lastly, 
revascularization can be completed by either percutaneous coronary intervention or coronary 
artery bypass surgery. These should be performed in patients that are symptomatic is ischemia, 
or if reperfusion may improve dysfunctional myocardium (Ezekowitz et al., 2017). 
Advanced HF. If devices cannot manage advanced HF, strategies include advanced 
mechanical devices, transplantation, or palliative therapies (Ezekowitz et al., 2017). Mechanical 
circulatory support (MCS) is a group of technologies that increase forward cardiac output in 
patients through the use of ventricular assist devices that augment or replace the ventricle 
(Ezekowitz et al., 2017). As well, if patients have severe refractory HF despite optimal therapy, 
cardiac transplantation can be considered (De Denus & White, 2019). Lastly, palliative care can 
be used in conjunction with other therapies that are intended to prolong life, including oral  
pharmacotherapy, surgery, implantable device therapy, and MCS (Ezekowitz et al., 2017).  
In summary, HF is a complex clinical syndrome involving abnormal heart function 
causing, or increasing the subsequent risk of, clinical symptoms and signs of reduced cardiac 
output and/or pulmonary or systemic congestion at rest or with stress (Ezekowits et al., 2017). 
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Optimal management for patients with HF presents many challenges to the patient, their family 
or caregivers, and the health care system. An accurate and timely diagnosis is critical to initiate 
treatment that will improve QoL, reduce hospitalizations, and prolong survival (Ezekowits et al., 
2017). AF and HF are two of the most common cardiac diseases and are intrinsically linked as 
they share common risk factors (AlTurki et al., 2019). The disorders perpetuate each other and 
create unique challenges to their management. The combined diseases lead to increased negative 
health outcomes, such as morbidity, mortality, and hospitalization, thus contributing to financial 
burdens on the healthcare system (AlTurki et al., 2019). 
Atrial Fibrillation and Heart Failure 
Although distinct, HF and AF are highly interrelated cardiovascular disorders. AF often 
contributes to worsening HF symptoms, and the prevalence of AF can give rise to, and parallels 
the severity of, HF ( Verbrugge & Mullens, 2014). The presence of AF is associated with a 
worse prognosis for overall survival. AF exacerbates HF due to decreased cardiac output, 
increased myocardial oxygen consumption, decreased coronary perfusion, and the development 
of tachycardia-induced cardiomyopathy (Ezekowits et al., 2017). The occurrence of one 
condition has implications for the treatment of the other, and the presence of one condition often 
hinders treatment for the other (Verbrugge & Mullens, 2014). As the population ages, the 
prevalence of AF and HF is expected to increase dramatically (Smigorowsky et al., 2017), and 
together they have the potential to cause a critical increase in healthcare burden and adversely 
impact patient experience or QoL (Andrade et al., 2018). The combination of HF and AF leads to 




AF and HF are two conditions that are predicted to dominate the next 50 years of 
cardiovascular care, as they are increasingly prevalent and associated with high morbidity, 
mortality, and healthcare costs. They are closely inter-related with similar risk factors, and 
usually affects the elderly with a significant burden of comorbidity (Kotecha & Piccini, 2015). 
Prevalent and Incidence. HF is three times more common among patients with AF 
compared to patients without AF (Wandell et al., 2018). The prevalence of AF in the presence of 
HF increases from < 10% in individuals with NYHA functional class I, to approximately 50% in 
individuals with NYHA functional class IV. Both diseases increase in incidence and prevalence 
with age and are associated with dramatic increases in mortality and morbidity, including 
increased hospitalizations, decreased QoL, and considerable financial healthcare burdens (Maisel 
& Stevenson, 2003). For example, a community based study by Chamberlain et al. (2011) 
determined that individuals with AF prior to HF had a 29% increased risk of death, whereas 
those who developed AF after HF exhibited a greater than two-fold increased risk of death. Thus, 
demonstrating that the combined disorders contributes to a greater risk of mortality. 
Cost and Burden on the Healthcare System. As it is evident that AF commonly 
coexists with HF and worsens prognosis, the financial burden on the healthcare system is 
substantially increased when both diseases occur together (Chugh et al., 2013). A Markov 
decision analysis model by Perez et al. (2011) measured rate control versus rhythm control for 
management of AF in the presence of HF. In 2009, costs were measured in U.S. dollars, and 
clinical outcomes in quality-adjusted life-years (QALY). Pharmacological rate control was less 
costly and more effective than rhythm control. Base case and probabilistic sensitivity analyses 
cost and effectiveness values for rate control were $7231 and 2.395 QALYs, whereas those for 
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rhythm control were $16,291 and 2.197 QALYs (95% UI 2.155-2.237 QALYs) (Perez et al., 
2011). As such, the study demonstrates that rate control is less costly and more effective than 
rhythm control, however both have financial implications on the healthcare system. 
Risk Factors. AF and HF often coexist, and underlying heart disease associated with HF 
tends to increase left atrial pressure, cause atrial dilation, and alter wall stress, which is an 
example of structural abnormalities (January et al., 2014). Many disease processes that 
predispose patients to HF, such as valvular heart disease, hypertension, diabetes, and coronary 
artery disease, are also risk factors for AF (McCance & Huether, 2019). Risk factors for 
developing AF include conditions that are found to promote atrial remodelling, which includes 
heart failure, ischemic heart disease, hypertension, obesity, obstructive sleep apnea, and 
rheumatic heart disease. Other classic cardiovascular disease risk factors, such as diabetes, 
advanced age, male sex, alcohol consumption, and smoking, also contributes to AF (Andrade et 
al., 2020; McCance & Huether, 2019). Additionally, echocardiographic findings that are 
commonly found in patients with HF, such as left atrial enlargement, increased left ventricular 
wall thickness, and reduced left ventricular fractional shortening, also predispose patients to the 
development of AF (Maisel & Stevenson, 2003). 
Pathophysiology 
Causality of AF and HF are highly interconnected. The pathophysiology of combined AF 
and HF involves alterations in neurohormonal activation, electrophysiologic parameters, and 
mechanical factors that consequently cause HF to predispose AF, and inadvertently for AF to 
exacerbate HF (Maisel & Stevenson, 2003). AF is a complication of many cardiopulmonary 
disorders, such as HF, and causes increased afterload, elevated filling pressures, and left atrial 
enlargement (Piccini et al., 2013). Specifically, AF causes reductions in cardiac output due to 
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shorter diastolic filling time, loss of atrial contractile function, and elevated filling pressures, in 
addition to myocardial dysfunction caused by tachycardia (Andrade et al., 2020). As such, AF 
results in structural abnormalities and electric remodeling changes that enhance susceptibility to 
HF (January et al., 2014; Maisel & Stevenson, 2003; Piccini et al., 2013). Additionally, age-
related declines in vascular compliance, increased population longevity, and the increasing 
prevalence of cardiovascular disease has led to a growing AF and HF epidemic (Piccini et al., 
2013). Tachycardia and shortening of diastolic filling time associated with irregular ventricular 
activation with AF further impair diastolic relaxation and promote HF, which further induces 
atrial remodeling leading to the preservation of AF (Staerk et al., 2017). 
Management 
Individuals with concomitant AF and HF respond differently to treatment than those with 
HF or AF alone. As such, there is a need to identify and treat according to best evidence to 
prevent adverse outcomes and reduce the burden that HF and AF are expected to have on global 
healthcare systems in the future (Kotchea & Piccini, 2015). For AF, the main goals of therapy 
are control of symptoms and prevent cardiac dysfunction with subsequent HF and/or 
hemodynamic compromise, as well as prevent arterial thromboembolism, including stroke. 
These goals are also appropriate in patients with HF, as symptoms are frequent and potentially 
disabling due to the interaction between the two conditions (Olshansky, 2019).  
There are two strategies used for medical therapy, including rate and rhythm control. 
Rate control includes medications and atrioventricular node ablation with pacing, whereas 
rhythm control includes AADs, as well as cardioversion and catheter ablation, which will be 
briefly discussed (Olshansky, 2019). 
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Pharmacological Interventions. There are various types of pharmacological agents used 
to treat AF and HF separately. Rhythm and rate control strategies are reasonable in patients with 
HFpEF or HFrEF. Rate control includes BBs are first line therapy due to their favourable effect 
on morbidity and mortality (January et al., 2014), as they prolong diastolic filling time, reduce 
myocardial ischemia, control hypertension, and prevent arrhythmias (Ezekowitz et al., 2017; 
Olshansky, 2019). While ND-CCBs, such as verapamil and diltiazem, should be avoided with 
HFrEF. If a patient is unable to receive either medication, digoxin may be considered (Wandell 
et al., 2018). Rhythm control therapy includes AAD therapy or ablation of AF to suppress the 
recurrence of AF. Some AADs, such as amiodarone and dronedarone, are not well tolerated by 
patients with HF due to adverse effects. These drugs have led to an increased risk of pump 
failure and arrhythmic deaths. As such, pharmacological rhythm control is not necessarily 
superior to rate control in influencing long term outcomes (Packer, 2020). 
Nonpharmacological Interventions. Pharmacology of rhythm and rate control strategies 
for AF are not always effective or tolerated in patients with HF (Andrade et al., 2020; Ezekowitz 
et al., 2017). Electrical cardioversion can be performed to return patients to normal sinus rhythm 
to help stabilize the patient and try HF management (Olshansky, 2019). Another management 
strategy includes catheter ablation for patients with symptomatic AF who have HF and failure of 
AAD therapy, rather than continued attempts with AAD therapy or no AAD therapy (Olshansky, 
2019). Catheter ablation has be shown to be a superior management strategy compared to 
pharmacotherapy, whether rate or rhythm control, for improving outcomes in patients with 
concomitant AF and HF (AlTurki et al., 2019).  
In summary, AF and HF are two epidemics of cardiovascular disease, and both diseases 
share similar risk factors and pathophysiology (Andrade et al., 2020; McCance & Huether, 
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2019). Combined AF and HF are increasingly prevalent and associated with high morbidity, 
mortality, and healthcare costs (Chugh et al., 2013). However, finding effective therapies for the 
population of interest is challenging, as treatments shown to be effective in one or other of these 
conditions alone have also been observed to have efficacy or safety concerns in patients with HF 
and AF combined. As such, there is an evident clinical need to optimally manage the 
concomitant diseases in order to prevent poor outcomes, as well as reduce the significant burden 
the diseases are predicted to have on healthcare systems (Kotech & Piccini, 2015). 
Primary Care Setting 
As with many other chronic cardiovascular conditions, the complex nature of AF and HF 
requires a systematic approach to management. Much of the initial management of AF can be 
provided by PCPs, with the support of specialist cardiology input to guide management decisions 
in selected AF patients who develop problems or complications (Andrade et al., 2020). While 
with HF, specialist supports are valuable even at an early stage, and often require ongoing 
partnerships between primary and speciality care providers. 
Due to the increasing prevalence of chronic conditions, healthcare systems are challenged 
to provide necessary care and enable patients to participate in their treatment plan (Watts et al., 
2009). As such, NPs play a key role in meeting these challenges and barriers to healthcare. NPs 
are able to diagnose, prescribe and order treatments, as they are independent practitioners that 
work collaboratively within a healthcare team (Smigorowsky et al., 2020). NPs are unique, as 
they use select medicine and advanced nursing skills that may result in greater benefits to 
patients and the healthcare system. As such, NPs are associated with decreased costs, increased 
patient engagement with their care, and improved QoL (Smigorowsky et al., 2020). In the 
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context of AF and HF, the NP in primary care are well situated to support patient care and to 
work alongside specialists, including cardiologists and NPs in the cardiac clinical setting. 
Support for patient self‐management, by providing education and training, can facilitate 
the long term care of patients with chronic diseases (Dennis et al., 2008). Specifically, self-
management involves daily management of chronic conditions over the course of an illness with 
the goal of improving health outcomes by enabling individuals to effectively manage their own 
illness (Andrade et al., 2020). The traditional provider-patient relationship shifts to shared 
decision making, where the patient is responsible for guiding their care in partnership with their 
health care providers. Key areas of focus include medical management by adherence to a 
therapeutic regimen, behaviour modification, and development of strategies to provide emotional 
and psychosocial support (Andrade et al., 2020). 
NPs have a key role in supporting self‐management, as they provide patients with 
essential tools to be successful in improving health outcomes (Watts et al., 2009). NPs possess 
skills that have been shown to be harmonious with behavioral health specialists, and therefore 
are qualified to manage patients with chronic diseases in outpatient settings (Watts et al., 2009). 
Patient-centred care requires collaboration between clinicians and knowledgeable 
patients, considering the best available evidence in addition to the patient’s values and 
preferences (Andrade et al., 2020). As such, education is also vital to the concept of self-
management, as it necessary for the patient’s perceived understanding about the causes, 
consequences, clinical manifestations, and controllability of their disease (Andrade et al., 2020). 
Also, patient and family education have been shown to improve clinical outcomes (Ezekowitz et 
al., 2017). Misalignment of the therapeutic interventions with the patient values and preferences 
can lead to dissatisfaction with therapy, nonadherence of treatment, and thus therapy 
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discontinuation, resulting in an increased risk of adverse outcomes such as stroke (Andrade et al., 
2020). Unfortunately, patients with cardiovascular diseases, such as AF, often have a poor 
understanding of the cause and consequences, such as risk of stroke (Andrade et al., 2020). 
Therefore, individualized patient education is able to provide accurate illness representation, 
improves compliance to treatment, manages therapeutic options and goals, relieves disease-
associated anxiety and stress, and promotes self-management (Andrade et al., 2020). As well,  
continuing medical education must be readily available for providers to help support knowledge 
translation and help foster evidence based research into clinical practice and navigate patients 
and providers between levels of care (Ezekowitz et al., 2017). 
Nurse Practitioner Role 
Management of AF in the presence of HF is relevant to NPs, as optimizing treatment of 
the combined disorders involves incorporating broad expertise (Verbrugge & Mullens, 2014). 
Addressing risk factors is a goal of therapy that can be effectively accomplished through a 
multidisciplinary management approach using subspecialists of cardiologists, in addition to other 
medical professionals, such as NPs (Andrade et al., 2018; Verbrugge & Mullens, 2014). NPs are 
not specialized in a particular chronic disease, however they receive advanced, formal training in 
primary care (Health Quality Ontario, 2013). For example, a study by Health Quality Ontario 
(2013) aimed to determine the effectiveness of specialized nurses managing chronic disease in 
patient care. Documents of various providers were assessed by reviewing patients’ charts in the 
diabetes subgroup analysis. The study demonstrated that NPs were more likely to provide 
education. As well, NPs provide a holistic approach to chronic illness management, including 
medication concerns and barriers to adherence (Watts et al., 2009). Specifically, NPs are 
competent in behavioral modification for chronically ill patients, which is valuable for practices 
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and approaches that related to self-management support. NPs coach patients to set goals and 
provide assistant to achieve these goals (Jeon & Benavente, 2016). Particularly, health coaching 
involves helping patients “gain the knowledge, skills, tools and confidence” (p. 24) to become 
active participants in their care to be able to reach their health goals (Bennett et al., 2010). Health 
coaching is emerging as an effective approach to improve patients’ behavior by empowering 
them to be the center of their health care needs. 
Physicians in primary care struggle to fit multiple agenda items into a 15-minute visit, 
and thus may not be able to meet every need of their patients with chronic conditions. Thus, half 
of patients leave primary care visits not understanding what was discuss, as only 9% of patients 
participate in decisions, and average adherence rates for prescribed medications are about 50%, 
and for lifestyle changes they are below 10% (Bennett et al., 2010). However, NPs are able to 
provide care with improved outcomes when compared to family physicians (Sciamanna et al., 
2006). For example, patients with coronary heart disease who were randomized to receive care 
from an NP with training to follow a treatment algorithm for one year were significantly more 
likely to achieve low-density lipoprotein cholesterol levels than those patients who were 
randomized to usual care with a family physician and/or cardiologist (Mundinger et a l., 2000). 
Thus, by NPs involving patients in the decision-making process encourages self-determination, 
self-responsibility, and ownership (Jeon & Benavente, 2016). As well, the NP and patient 
relationship is a cost‐effective strategy to promote patients’ health (Hayes & Kalmakis, 2007). 
In summary, NPs address major deficiencies in chronic illness management through 
providing education and promoting self‐management to patients and their families (Watts et al., 
2009). NPs have been increasingly involved in providing pre-emptive care with an expanded 
scope of practice through coaching patients to set and achieve goals, thus empowering them to 
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coordinate their own care (Jean & Venavente, 2016). Thus, management of chronic illness is a 
longitudinal process where NPs play a key role, as NPs have unique skills that are well 
positioned to foster patient‐centered care (Andrade et al., 2020). As such, the involvement of 
NPs managing combined AF and HF leads to cost savings, thus reducing the burden on the 
healthcare system by increasing adherence to treatment plans and improving clinical and patient-
reported outcomes (Smigorowsky et al., 2017).  
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CHAPTER II: METHODOLOGY 
The integrative review method is designed to summarize existing literature in a 
systematic process, allowing for a more comprehensive understanding of a particular healthcare 
problem (Whittemore & Knafl, 2005). By incorporating diverse methodologies, integrative 
reviews contribute directly to nursing science, in addition to informing wider research, practice, 
and policy initiatives, and are commonly used to support evidence-informed practice 
(Whittemore & Knafl, 2005). The purpose of this integrative literature review is to identify 
strategies to best manage and support patients with AF in the presence of HF in primary care 
settings. As such, there is an opportunity to better understand the care of patients with these 
challenging conditions, which in turn may inform initiatives that can improve patient outcomes, 
reduce hospitalizations, and decrease healthcare costs. 
Integrative Review Methods 
 Integrative reviews allow for various perspectives on an issue to be organized 
systematically by incorporating diverse forms of literature. They capture the context, processes, 
and subjective components of the topic, which aids in forming nursing science, as well as 
informing research, practice, and policy initiatives (Whittemore & Knafl, 2005). In comparison, 
systematic reviews have more of an emphasis on the formal assessment of the quality of the 
study, as they combine the evidence of multiple studies focused on a specific clinical problem to 
inform practice (Whittemore & Knafl, 2005).  
Integrative reviews allow for the inclusion of diverse methodologies and are able to 
contribute to evidence‐based practice for nursing. For example, a guideline by Andrade et al. 
(2018) was developed through studies and literature, and provides periodic reviews of new 
information and developed focused updates that discuss clinically relevant advances for the 
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management of AF. However, further opportunities exist to understand the management of 
concomitant AF and HF, which in turn may help inform clinicians about the risks and benefits of 
therapeutic options. 
The literature review will follow the integrative review methodology as delineated by 
Gray et al. (2017). In congruence with this approach, the following review stages were 
undertaken: 1) Development of the research question, 2) Preliminary review of the literature and 
focused search, and 3) Analysis and reporting 
Development of the Research Question and Search Strategy 
The impetus for this review was grounded in the professional experiences and interest of 
the writer. Over four years, the writer has worked in critical care, providing direct care to those 
living with cardiac disorders. It is these clinically-grounded experiences that has led her to 
investigate the management of concomitant cardiac diseases, specifically combined AF and HF. 
The high volume of patients seen in emergency departments with unmanaged AF, in addition to 
a subset of HF, intrigued the writer to explore the most optimal approach to support patients and 
avoid hospitalizations, thereby reducing the burden on the healthcare system. By exploring the 
topic’s relevance and identification of the specific problem, the research question was developed 
by following the population, intervention, and evaluation (PIE) approach (Gray et al., 2017). The 
population consists of outpatients with HF. The intervention includes the management of AF 
with a focus on arrythmia care. The effect is an improvement in outpatient management of AF in 
the context of HF, and therefore a reduced burden on the healthcare system. The formulated 
question is, “How can the NP best manage HF patients with AF in outpatient settings to help 
reduce the burden on the healthcare system?” With the above in mind, the strategies for the 




A health librarian at University of Northern British Columbia’s (UNBC) library (Dr. T. 
Fyfe) was consulted during the literature review search. A preliminary literature search was 
performed using electronic databases accessed through UNBC’s library, including Cumulative 
Index of Nursing and Allied Health Literature (CINAHL [ESBCO]), MEDLINE (Ovid), and 
Cochrane Reviews (EBM). The databases were selected as they provided access to full-text 
articles and professional and academic literature. Specifically, CINAHL was chosen, as it 
provides full text for more than 770 journals related to nursing and allied health journals. 
Additionally, the Cochrane Database of Systemic Reviews was utilized, as it is the leading 
database for systematic reviews in healthcare. Lastly, MEDLINE was selected, as it contains 
citations from over 4, 8000 current biomedical journals pertaining to medicine, nursing, and the 
health care system (Gray et al., 2017). As such, the above databases represent a wide range of 
sources for primary research articles and systematic reviews that pertain to areas of medicine, 
nursing, and healthcare, which are relevant to the topic of AF in the context of HF, with a focus 
on arrythmia care. 
Search Terms 
Through searching the background literature and consulting with the health librarian, 
selected search terms were selected. Search terms and MeSH terms were utilized and Boolean 
operations, such as “AND”, “OR”, and “NOT,” were used to group or exclude keywords during 
the search – see table 1. Additionally, the truncation (*) symbol was used to retrieve additional 









“heart failure” OR “congestive heart failure” OR “cardiac failure” OR 
“chf” OR “chronic heart failure” OR “congestive heart failure” AND 
“atrial fibrillation” OR “afib” OR “af” 
Intervention 
Managing AF 
“antiarrhythmic drugs” OR “rate control” OR “rhythm control” OR 
“catheter ablation” OR “physicians, family" OR "family nurse 
practitioners" OR "primary health care” OR “family practice” 
Evaluation 
Reduced burden 
on the health care 
system 
“health care costs” OR outcomes OR “preventative health care” OR 
“readmission” OR “hospitalization”  
 
Preliminary Review of the Literature and Focused Search 
Each database was individually searched as found in Appendix A. Filters were applied, 
including the English language. After the initial database search was completed, a total of 1326 
articles were found and moved into Zotero (n.d.), which is a standard software that manages 
references for bibliographic data and research materials. The duplicate articles were removed, 
leaving 1237 articles remaining. These article’s titles were screened for relevance to the research 
question, 221 articles remained. The 221 articles were read and also screened for relevance. The 
remaining 32 articles were retrieved in full text and were read closely. These were then reviewed 
according to the eligibility criteria. After a thorough review of the remaining 32 records by 
considering the inclusion and exclusion criteria, a focused search was undertaken. The search 
produced a more manageable body of literature for a focused review, resulting 20 eligible studies 
included in the synthesis. See the Appendix B for a PRISMA flow diagram to help illustrate how 
the applicable articles were screened.  
Eligibility Criteria 
Eligibility was established by applying predetermined inclusion and exclusion criteria, 
which were monitored throughout the literature search and guided the selection process of the 
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articles included in the literature review. The inclusion and exclusion criteria were chosen to 
reflect the diversity needed to address the clinical question, as well as support the literature 
selection process to ensure the information would be translatable into a primary care setting. 
Inclusion Criteria. References in the English language original research, such as 
controlled studies, systematic reviews, and articles from peer-reviewed journals were included. 
Studies from developed countries were chosen, as they are the most relevant documents that 
relate to the Canadian healthcare system. Literature from 2015 to present were included with the 
intention of capturing the most recent practices and recommendations, as the literature has been 
rapidly evolving with major revisions to the AF and HF guidelines. Articles pertaining to both 
AF and HF were included. Lastly, participants included were adults aged 18 years or older, as 
AF and HF are problems in the aging population (Smigorowsky et al., 2017), and seldom studies 
were found in the literature search with patients younger than 18 years of age. 
Exclusion Criteria. Articles that focussed on teaching or education were excluded, as the 
focus of the research question is on clinical content. Studies with a focus on acute 
decompensated HF, rapid AF, and hemodynamically unstable samples were excluded from the 
study, as the management for acute episodes are not implemented in a primary care setting. 
Youth and children less than 18 years of age were excluded as this group is beyond the scope of 
this literature review. Articles pertaining to only HF or AF alone were excluded, as there is 
already a great body of research for managing both disease independently, and the focus was 
managing both diseases together. 
Analysis and Reporting 
 The review is guided by the integrative review approach and framework that directed the 
initial literature analysis involved three different appraisal tools. Specifically, an abstraction 
44 
 
analysis was conduced using the Critical Appraisal Skills Programme (2013) appraisal tools for 
the single studies. In addition, from Davies & Logan (2018) and a worksheet for appraising 
systematic reviews was utilized for the eight systematic studies. A total of 20 articles were 
critically appraised for content and then organized thematically. A matrix was developed to 
document the key aspect of the studies and support the analysis of the articles. Articles were 
reviewed in full and organized thematically in a matrix, which can be found in appendix (C). 
Through analyzing the final articles in the integrative literature review, three key themes 
emerged. The matrix was helpful in identifying areas of overlaps and focal topics. These were 
found to reflect key health service outcomes, including areas that indicate burden and impacts for 
both the patient and healthcare system. The themes include: 1) Catheter ablation is superior to 
medical therapy, 2) Safety considerations, and 3) Differing treatment for HFrEF and HFpEF.  
 Themes were developed and reported descriptively, and key studies were highlighted and 
a synthesis of the key outcomes provided. An integrative review approach was used to explore 
the literature relating to concomitant AF and HF. A systematic search was undertaken and 
relevant literature was captured and screened for eligibility. The final cohort of articles were 
reviewed in detail and were analyzed thematically. Descriptive accounts of the key themes are 




CHAPTER III: FINDINGS 
 In the findings chapter, a critical review of the literature on the management of 
concomitant AF and HF will be presented. This is supplemented by a literature review matrix of 
the single studies, as well as the systematic reviews, and meta-analyses, which organizes the 
findings of the abstracted documents and provides relevant research data for optimally managing 
combined AF and HF. The matrix can be found in Appendix C. 
The integrative literature review included a final cohort of eight systematic reviews 
and/or meta-analyses and 12 single studies, dating from 2015 to present. Of the single studies, 
four were conducted in the USA (Black-Maier et al., 2018; Di Biase et al., 2016; Kuck et al., 
2019; Marrouche et al., 2018), one in Korea (Yu et al., 2018), one in Germany (Eitel et al., 
2019), four in Japan (Fukui et al., 2020; Ichijo et al., 2018; Machino-Ohtsuka et al., 2019; 
Saksena et al., 2018), and one in China (Geng et al., 2017). All articles were quantitative, with a 
clinical focus on the treatment of combined AF and HF. Of the single studies, six studies focused 
on a HFrEF (AlTurki et al., 2019; Di Biase et al., 2016; Eitel et al., 2019; Geng et al., 2017; 
Kuck et al., 2019; Marrouche et al., 2018), two studies focused on HFpEF (Fukui et al., 2020; 
Machino-Ohtsuka et al., 2019), and five studies compared the effects on HFrEF and HFpEF 
(Black et al., 2018; Eitel et al., 2019; Hess et al., 2020; Ichijo et al., 2018; Sasken et al., 2018). 
Four studies included patients with HF NYHA class ≥ two (Di Biase et al., 2016; Eitel et al., 
2019; Geng et al., 2017; Marrouche et al., 2018). Two studies did not specify ejection fraction or 
NYHA class (Yu et al., 2018; Sasken et al., 2018). One study specified persistent type of AF (Di 
Biase et al., 2016), one specified non-paroxysmal (Fukui et al., 2020), and one specified 
paroxysmal (Ichijo et al., 2018). Seven studies included two or more types of AF, such as 
paroxysmal, persistent, and/or permanent AF (Black-Maier et al., 2019; Eitel et al., 2019; Geng 
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et al., 2017; Kuck et al., 2019; Machino-Ohtsuka et al., 2019; Marrouche et al., 2018; Saksena et 
al., 2018). One study did not specify any type of AF (Yu et al., 2018). There were also seven 
single studies that were retrospective (Black-Maier et al., 2018; Fukui et al., 2020; Gene et al., 
2017; Ichijo et al., 2018; Machino-Ohtsuka et al., 2019; Sasken et al., 2018; Yu et al., 2018). 
 Despite attempts to capture literature of direct relevance to the primary care setting, there 
was a lack of primary care specific studies, and thus complexities for generalizing the results to 
an outpatient setting occurred. Likewise, synthesizing the articles within the review made it 
evident that the body of literature is very diverse, therefore creating challenges for making 
meaningful comparisons or robust recommendations. However, through analyzing the final 
articles, three key themes emerged including: 1) Catheter ablation is superior to medical therapy, 
2) Safety considerations, and 3) Differing treatment for HFrEF and HFpEF. The discussion of 
the themes will be facilitated based on the data obtained through reviewing multiple studies with 
a similar focus. As the topic is centered on the treatment of two dominant cardiovascular 
conditions, the body of literature is also quantitative, meaning that the accounts of lived 
experience are also not well addressed in the contemporary literature. 
Catheter Ablation is Superior to Medical Therapy 
 When determining the best management strategy for AF in HF patients, it is important to 
be aware of the therapies with the most optimal patient outcomes. There are clear guidelines for 
how to manage AF and HF separately, however, there is a lack of a clear consensus for treating 
the combined diseases. Thus, PCPs, in consultation with cardiac specialists, are often faced with 
the need to determine therapeutic strategies without strong guidance. In the literature, various 
studies were identified and reviewed that aimed to determine if catheter ablation was more 
effective than medical therapy with outcomes of rehospitalizations, AF recurrence, mortality 
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rates, QoL and functional capacity, and/or improved LVEF. A total of fifteen studies addressed 
the idea of catheter ablation being superior to medical therapy, eight of which were systematic or 
meta-analyses (AlTurki et al., 2019; Chen et al., 2020; Ma et al., 2020; Ruzieh  et al., 2019; Smer 
et al., 2018; Turagam et al., 2019; Xu et al., 2019; Zhu et al., 2016), and seven of which were 
single studies (Di Biase et al., 2016; Fukui et al., 2020; Geng et al., 2017; Ichijo et al., 2018; 
Machino-Ohtsuka et al., 2019; Marrouche et al., 2018; Yu et al., 2018).  
Through examining the literature, catheter ablation use led to significant improvements in 
rehospitalization, AF recurrence, and morality rates, and suggested a strong association with an 
improvement in QoL and functional capacity, as well as improved LVEF. The articles focused 
on the use of tools to manage the arrhythmia, of which most were comparing newer catheter 
ablation techniques to traditional medical regimes using rate and/or rhythm control. See table 2. 
Table 2  









AlTurki et al. (2019) X X X X X 
Chen et al. (2020) X X X X X 
Di Biase et al. (2016)  X X X   
Fukui et al. (2020) X X    
Geng et al. (2017) X X X   
Ichijo et al. (2018) X X X   
Machino-Ohtsuka et al. 
(2019) 
X  X 
 
 
Marrouche et al. (2018) X X X   
Ma et al. (2020) X X X X X 
Ruzieh et al. (2019) X X X X X 
Smer et al. (2018) X X X X X 
Turagam et al. (2019) X  X X X 
Xu et al. (2019) X  X   
Yu et al. (2018)   X   
Zhu et al. (2016)    X X 
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 The theme of catheter ablation being superior to medical therapy will be discussed below. 
It is important to emphasize that the Catheter Ablation versus Standard Conventional Therapy in 
Patients with Left Ventricular Dysfunction and AF (CASTLE-AF) trial developed by Marrouche 
et al. (2018) made a significant impact on the management of concomitant AF and HF. In 
contrast to previous trials, the hard primary end point of death or hospitalization for HF was 
evaluated. Participants were followed for up to 60 months to assess long-term outcomes, and the 
mortality benefit of ablation in the trial did not arise until after three years. Patients with both 
paroxysmal and persistent AF were both included, and both conditions were shown to benefit 
from catheter ablation. There was no focus on a specific strategy, such as rate control compared 
to rhythm control, or choice of AADs in the medical-therapy group, as previous studies had not 
shown one strategy or drug to be superior to another.  The study was evolutionary for the 
subpopulation of interest, as it peaked other studies to examine the same, thus contributing to 
major practice considerations and the inclusion of catheter ablation in guidelines. 
Rehospitalizations 
The analysis of the literature demonstrated that many studies sought to determine the 
impact of different interventions, such as catheter ablation and pharmacotherapy of rhythm or 
rate control, on rehospitalization rates for patients with concomitant AF and HF. Thirteen studies 
discussed rehospitalization rates for patients with HF and AF undergoing catheterization as 
compared to pharmacotherapy, of which seven were systematic studies and/or meta-analyses 
(AlTurki et al., 2019; Chen et al., 2020; Ma et al., 2020; Ruzieh et al., 2019; Smer et al., 2018; 
Turagam et al., 2019; Xu et al., 2019) and six were single studies (Di Biase et al., 2016; Fukui et 
al., 2020; Geng et al., 2017; Ichijo et al., 2018; Machino-Ohtsuka et al., 2019; Marrouche et al., 
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2018). The analysis of the studies vastly demonstrate that catheter ablation is associated with a 
decrease, or freedom from, HF-related hospitalizations compared to pharmacotherapy. 
A meta-analysis by Smer et al. (2018) was performed according to the Preferred 
Reporting Items for Systematic Reviews and Meta‐Analyses statement. The methods of the 
statistical analysis were rigorous and thorough, as two authors independently searched databases 
from January 1966 to February 2018, and the selected manuscripts and review articles were 
manually searched for additional studies. A total of 1,597 articles were screened, however only 
six trials with a total of 775 patients met the inclusion criteria, which was considered to be a 
small sample size and questions the potential generalizability of the findings. There were 388 in 
the catheter ablation group and 387 in the medical therapy group, and a selection bias occurred 
due to the type of patients offered to participate in the randomized control trials. Specifically, 
those with advanced HF and NYHA class IV were mostly excluded from these studies due to the 
likelihood of not having favourable outcomes. The patients included were younger males with 
moderately decreased LVEF, shorter duration of persistent AF (mean 18.5 months), and less 
likely to have coronary artery disease. Thus, the analysis results may not be useful for older 
patients with severely depressed LVEF and/or longer duration of AF. The meta-analysis aimed to 
compare catheter ablation to medical therapy in patients with AF and HFrEF, and determined 
that ablation of AF was associated with significantly less HF hospital readmissions compared to 
medical rate and/or rhythm control (CI 0.32‐0.78, p=0.002). Similar findings were also found in 
systematic reviews and meta-analyses by AlTurki et al. (2019), Chen et al. (2020), Ma et al. 
(2020), Ruzieh et al. (2019), and Turagam et al. (2019), demonstrating that the rate of HF-related 
hospitalizations were significantly lower in catheter ablation groups than medical therapy groups. 
In these studies, HF hospitalizations varied with ablation verses pharmacotherapy (95% CI 0.44-
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0.71, p<0.0001; 95% 30.6% vs. 47.5%, p=0.003; 95% CI 0.46 - 0.66; 26.7% vs. 45.1%, 95% CI 
0.29 – 0.64, p<0.001; 16.4% vs. 27.6%, CI 0.39 to 0.93, respectively). 
A retrospective, non-randomized study by Ichijo et al. (2018) also discussed catheter 
ablation and medical therapy, however, specifically compared freedom of HF-related unplanned 
hospitalizations between HFrEF and HFpEF. The analysis of the study demonstrated that for 
HFrEF patients, freedom of HF-related unplanned hospitalizations at 1, 2, 3, and 4 years after the 
initial procedure was 97.6%, 97.6%, 97.6%, and 97.6%, respectively. For HFpEF patients, HF-
related hospitalizations were observed in 3.6% post-AF ablation, and at 1, 2, 3, and 4 years after 
the initial procedure was 96.2%, 96.2%, 96.2%, and 96.2%, respectively. 
Alike to the above single studies or systematic reviews/meta-analyses, Fukui et al. (2020) 
conducted a retrospective study with a Kaplan‐Meier curve analysis that revealed significantly 
more patients receiving ablation of AF were free from HF rehospitalization compared to 
conventional pharmacotherapy of AADs and/or BBs in patients with HFpEF after a mean 
follow‐up of 792 ± 485 days (p=0.0039). As well, catheter ablation of AF was the only 
preventive factor of HF rehospitalization (OR = 0.15; 95% CI 0.04‐0.46; p <0.001), and all‐cause 
rehospitalization was significantly lower in ablation group compared to the control group 
(p=0.0284). The study also draws attention to the findings of Marrouche and colleagues (2018), 
who found that fewer patients receiving catheter ablation compared to the medical therapy were 
hospitalized for worsening HF (20.7% vs. 35.9%; 95% CI 0.37-0.83; p=0.004). While the 
majority of the studies found statistically significant improvements in hospitalization, one 
retrospective cohort study by Geng et al. (2017) investigated the relationship between catheter 
ablation and medical therapy did not find a statistically significant association for unplanned 
hospitalizations (16.1% vs. 10.0%, p=0.140). 
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Three studies explicitly discussed the types of medication given to manage AF and HF 
together, all of which are in agreeance that medical therapy is associated with increased HF-
related hospitalizations. For example, the quantitative, multi-center, open labelled, randomized, 
parallel-group study by Di Biase et al. (2016) aimed to determine if catheter ablation is more 
effective than amiodarone for the treatment of persistent AF in patients with HF. In total, 866 
patients were screened, 331 were eligible for inclusion. In total, 203 consented and were 
included in the study and randomly assigned to receive catheter ablation (n=102) or amiodarone 
therapy (n=101). Patients were randomly assigned by a 1:1 ratio to undergo catheter ablation for 
AF or to receive amiodarone. Baseline characteristics in the catheter ablation group included 
ages 62 ± 10, 77% male patients, and AF duration of 8.6 ± 3.2 months. In the amiodarone group, 
baseline characteristics included ages 60 years ± 11, 74% male, and AF duration of 8.4 ± 4.1 
months. A secondary end point was unplanned hospitalization rates, which was lower in the 
catheter ablation group (31%) compared to the amiodarone group (57%) (p<0.001). The 
methodology was rigorous, as a computerized central randomization scheme was undertaken 
using block randomization, and sets of randomly selected blocks were provided to the sites. The 
study also included 30% oversampling for attrition and sampling was based on 80% power 
analysis. However, there was a lack of formal comparison with a rate control strategy or 
followed up period longer than 24 months. Also, sotalol and dofetilide are alternative AAD 
medications available for managing combined AF and HF, however were not tested in the trial. 
In another retrospective observational study, Machino-Ohtsuka et al. (2019) investigated 
if the maintenance of sinus rhythm was associated with better prognosis compared with rate 
control in patients with concomitant HFpEF and AF in 283 patients with HFpEF and AF. Of 
these, 107 patients achieved maintenance of sinus rhythm by catheter ablation and/or AADs 
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(rhythm control) and 176 were treated with rate control medications, such as BBs, CCBs, and 
digoxin. The analysis of the study determined that the rhythm control group had a lower 
incidence of hospitalization even after adjustment with propensity scoring (adjusted HR, 0.27; 
95% CI 0.12–0.61; p=0.002). Lastly, a meta-analysis by Xu et al. (2019) aimed to investigate the 
effects of BBs on outcomes in patients with chronic HF and AF. Six studies, including four post-
hoc analysis of randomized control trials and two observational studies, showed the effect of 
BBs treatment on hospitalization for HF. Although not explicitly comparing BBs to catheter 
ablation, the analysis of the data indicates that treatment with BBs was not associated with a 
reduction of hospitalization for HF (RR = 1.03; 95% CI 0.89–1.21, P = 0.66), thus favouring 
catheter ablation. 
Overall, although one study did not demonstrate a strong correlation of ablation of AF in HF 
patients and reduced hospitalization rates (Geng et al., 2017), the majority of the study analyses 
demonstrated statistically significant evidence that catheter ablation is an important therapeutic 
option. Particularly, catheter ablation has been proven to be superior to conventional 
pharmacotherapy for reducing HF hospitalizations. 
AF Recurrence 
The literature explored the impact of interventions, including catheter ablation and 
pharmacotherapy of rhythm or rate control, on recurrence of AF arrhythmia for patients with 
combined AF and HF. In particular, ten studies analyzed the AF reoccurrence rate for patients 
with HF undergoing catheter ablation of AF, as compared to pharmacotherapy. Five of the 
captured studies were systematic reviews and/or meta-analyses (AlTurki et al., 2019; Chen et al., 
2020; Ma et al., 2020; Ruzieh et al., 2019; Smer et al., 2018) and five were single studies (Di 
Biase et al., 2016; Fukui et al., 2020; Geng et al., 2017; Ichijo et al., 2018; Marrouche et al., 
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2018). The analysis of the studies greatly demonstrate that catheter ablation is associated with a 
decrease in AF recurrence compared to pharmacotherapy. 
A systematic and meta-analysis study by Ruzieh et al. (2019) identified 1,884 studies, of 
which seven full texts met inclusion criteria. A total of 856 patients were included, of which 429 
patients were randomized to catheter ablation and 427 patients were randomized to medical 
therapy alone. There was an average age of 63.4 years and a mean follow-up time of 15.2 
months. The proportion of males ranged between 73% and 96%. Mean LVEF was 29.9%. The 
vast majority of patients had persistent AF, and NYHA Functional Classification II-III. The aim 
of the study was to determine if catheter ablation for AF is superior to medical therapy in 
patients with coexisting AF and HF. The results confirmed that significantly more patients in the 
AF ablation group were in sinus rhythm at the end of trials compared to the medical therapy 
group (73.7% vs. 18.3%, 95% CI 10.2 – 111.7; p<0.001). To achieve this high success rate from 
AF ablation, repeat intervention was allowed in all trials and the percentage of patients who 
underwent repeat ablation ranged from 19% to 54%. Despite the rigorous methodology, a 
limitation included patients not being blinded, as none of the trials had a placebo group. There 
was also an overall representation of males, as the inclusion of women was relatively low. 
Alike to Ruzieh and colleagues (2019), the analysis of the studies by Chen et al. (2020) 
and Ma et al. (2020) determined that catheter ablation rhythm control was associated with 
significantly lower arrhythmia recurrence. Specifically, Chen et al. (2020) determined that 
catheter ablation rhythm control was associated with significantly lower arrhythmia recurrence 
(29.6% vs. 80.1%; 95% CI 0.01–0.14, p< 0.00001). Similarly, Ma et al. (2020) concluded that 
64.2% (95% CI 49.4% to 79.0%) of patients undergoing catheter ablation were free from AF 
after the first procedure. As well, catheter ablation was repeated in patients with recurrent AF, 
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and at the end of follow-up 74.9% (95% CI 63.2% to 86.5%) of patients receiving catheter 
ablation had freedom from AF, and AF burden was 14.2% (95% CI -10.7% to 39.1%). 
Comparable to the above studies, the analysis of the CASTLE-AF trial by Marrouche et 
al. (2018) determined that 63.1% of the patients receiving AF ablation and 21.7% receiving 
medical-therapy (p<0.001) were in sinus rhythm at the 60-month follow-up period and had not 
had recurrence of AF since the previous follow-up visit at 48 months. The adjudicated rate of 
recurrence of AF in the ablation group among those who had actually undergone ablation and 
who were followed for up to 60 months was 50.0%, with an average of 1.3 ± 0.5 ablation 
procedures per treated patient. As well, a single center, retrospective non-randomized study by 
Ichijo et al. (2018) aimed to determine the long-term effects of ablation of AF in patients with 
HF. For patients with HFrEF, 92.1% of patients were free from any recurrent atrial arrhythmias, 
and arrhythmia-free survival at 1, 2, 3, and 4 years after the last procedure was 95.3%, 88.7%, 
88.7%, and 88.7%. For patients with HFpEF after 1.4 ± 0.5 procedures, 85.5% of patients 
remained free from any recurrent atrial arrhythmias, and arrhythmia-free survival at 1, 2, 3, and 4 
years after the last procedure was 90.0%, 84.6%, 79.3%, and 79.3%. 
In contrast, a retrospective study by Fukui et al. (2020) attempted to determine the 
relationship between catheter ablation and medical therapy in regards to the recurrence of AF, 
however, insignificant results were generated. Although the analysis of study findings illustrates 
that patients undergoing ablation of AF had advantages, such as lower rehospitalization rates, the 
recurrence of AF did not differ compared to the control group receiving AADs and/or BBs after 
a mean follow‐up of 703 ± 424 days (p=0.119). 
Two studies addressed catheter ablation and medical therapy specific to patients with AF 
and HFrEF. Systematic reviews by Smer et al. (2018) and AlTurki et al. (2019) compared 
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catheter ablation to medical therapy in patients with AF and HFrEF. Smer and colleagues (2018) 
determined that ablation of AF was associated with freedom from AF higher in patients who had 
underwent catheter ablation compared to medical therapy (CI 6.94‐84.41, p<0.00001). As well, 
of the seven randomized control trials included in AlTurki et al. (2019)’s systematic review and 
meta-analysis, six reported arrhythmia-free survival at the end of follow-up as the measure of 
success of catheter ablation in maintaining sinus rhythm. In particular, one study reported an 
arrhythmia free survival of 50%, whereas all other studies reported an arrhythmia free survival of 
over 70% at the end of follow-up. The highest reported survival was 92% in one study, and in the 
longest reported follow-up, which was 37 months in the CASTLE-AF trial, the arrhythmia free-
survival rate was 75% in patients who underwent catheter ablation. 
Two studies examined the specific types of medication given to manage combined AF 
and HF and compared the results to catheter ablation. In particular, the retrospective cohort study 
by Geng et al. (2017) compared catheter ablation of AF in patients with HF compared to rate 
control medical strategies, specifically BBs and/or digoxin. A total of 394 patients with AF and 
HF were included. Of those, 90 patients received AF ablation and the rest received medical of 
rate control therapy. Patients in the rate control group were older (73.0 ± 10.7 years vs. 64.7 ± 
9.4 years, p<0.001) and had higher risk of stroke as determined by the CHA2DS2-Vasc score 
(3.5 ± 1.5 vs.2.3 ± 1.5, p<0.001) when compared with those in catheter ablation group. There 
were more patients with a previous histories of stroke (23.4% vs.13.3%, p=0.041) and with 
persistent or long-standing persistent AF (81.2% vs.66.7%, p=0.003) in rate control group than 
in catheter ablation group. The methodology was rigorous and thoroughly explained, and the 
authors applied propensity score matching to adjust for potential confounding factors. Thus, 
imbalanced baseline characteristics were added into a logistic regression model to help remove 
56 
 
biases. Limitations to the study includes a short term follow-up period, and sixteen patients were 
lost to follow-up. After a mean follow-up of 13.5 ± 5.3 months, 82.2% of patients in catheter 
ablation group had total freedom from AF, whereas all patients in the rate control group 
remained in paroxysmal and persistent or long-standing persistent AF. These findings were 
consistent with the study by Di Biase et al. (2016), which aimed to determine if catheter ablation 
is more effective than amiodarone for the treatment of persistent AF in patients. At the end of the 
study, 70% of patients in the catheter ablation group did not have recurrence of AF after an 
average of 1.4 ± 0.6 procedures, in comparison with 34% (95% CI 25% – 44%) in patients 
receiving amiodarone.  
Aside from Fukui et al. (2020)’s study results, the majority of captured studies 
demonstrate statistical significance that ablation of AF in patients with HF reduced AF 
recurrence rates, and the results are strong enough to have the therapeutic strategy as an option in 
a clinical setting. Therefore, the assessments of the studies have determined catheter ablation is 
superior to conventional pharmacotherapy for improving AF recurrence rates. 
Mortality  
The literature explored the impact of interventions, including catheter ablation and 
pharmacotherapy of rhythm or rate control, on mortality rates for patients with concomitant AF 
and HF. Thirteen studies discussed mortality rates for patients with HF undergoing 
catheterization compared to pharmacotherapy, of which seven were systematic and/or meta-
analyses (AlTurki et al., 2019; Chen et al.,2020; Ma et al., 2020; Ruzieh et al., 2019; Smer et al., 
2018; Turagam et al., 2019; Xu et al., 2019) and six were single studies (Di Biase et al., 2016; 
Geng et al., 2017; Ichijo et al., 2018; Machino-Ohtsuka et al., 2019; Marrouche et al., 2018; Yu 
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et al., 2018). The analysis of the studies considerably demonstrated that catheter ablation of AF 
in HF patients is associated with a decrease in mortality compared to pharmacotherapy. 
Seven studies, including three systematic and/or meta-analyses and four single studies, 
aimed to determine if catheter ablation was superior to medical therapy in terms of mortality in 
patients with combined AF and HF. A stratified pooled analysis of randomized data by Turagam 
et al. (2019) evaluated the benefits of medical therapy and catheter ablation of rhythm control for 
the management of combined AF and HF. Six randomized control trials were included with a 
total of 775 participants. The trials had at least a six month follow-up, adults aged 18 years or 
older, compared AF ablation with standard drug therapy in patients with HF, and reported one or 
more clinical outcomes. Retrospective studies, studies with no comparative group, non-
randomized trials, case reports, editorials, reviews, expert opinion, and studies published in a 
language other than English were excluded. The authors developed and followed a protocol for 
the systematic review and meta-analysis. The methodology was rigorous, as two investigators 
independently performed searches of various databases without language restrictions for articles 
and abstracts published between January 2005 and October 2018. Two investigators also 
independently screened all titles and full-text versions of the relevant randomized control trials.  
The purpose of the study was to compare benefits and harms between catheter ablation 
and pharmacotherapy in adult patients with AF and HF. The analysis of the study determined 
that compared with drug therapy, AF ablation reduced all-cause mortality (9.0% vs. 17.6%; 95% 
CI 0.33 to 0.81). A limitation of the study includes the results being driven primarily by the 
largest trial, CASTLE-AF, although there were six randomized control trials included. As well, 
patient selection bias may have occurred, as patients selected for a randomized catheter ablation 
trial may have been healthier than those who are receiving only medical management, 
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particularly patients included were relatively young (aged 55 to 64 years). Additionally, the 
participants and physicians were not blinded to treatment assignment, thus, medical care and 
follow-up may have differed after ablation. Alike to Turagam and colleagues (2019), two meta-
analyses of randomized control trials by Ma et al. (2020) and Chen et al. (2020) aimed to 
compare catheter ablation and pharmacotherapy in adult patients with AF and HF. The studies 
demonstrated that catheter ablation was shown to be superior to conventional pharmacotherapy 
for improving all-cause mortality (95% CI 0.35 – 0.76; 9.0% vs. 17.6%, risk ratio, 0.52 [95% CI 
0.33 to 0.81]; 10.7% vs. 18.9%; p=0.0003, respectively). 
In the CASTLE-AF trial by Marrouche et al. (2018), the purpose was to assess whether 
catheter ablation lowers morbidity and mortality compared to medical therapy of rate or rhythm 
control in patients with AF in the context of medically managed HF. The authors demonstrated 
that rhythm control of catheter ablation is more beneficial than medical therapy in preventing 
death, as significantly fewer patients in the catheter ablation group died from any cause (13.4% 
vs. 25.0%; 95% CI 0.32- 0.86; p=0.01) or died from cardiovascular causes (11.2% vs. 22.3%; 
95% CI 0.29-0.84; p=0.009), compared to medical therapy of rate or rhythm control for AF. 
Similarly, the quantitative, multi-center, open labelled, randomized, parallel-group study by Di 
Biase et al. (2016) had a secondary end point of mortality. The assessment of the study 
demonstrated that mortality was significant lower in the catheter ablation group (8%) compared 
to participants receiving amiodarone therapy (18%), with a P value of 0.037 determining 
statistical significance. As well, a single center, retrospective non-randomized study by Ichijo et 
al. (2018) aimed to address the long-term effects of ablation of AF in patients with HF. In the 
HFrEF group, one patient died due to an acute myocardial infarction during the follow-up period. 
Freedom from a composite endpoint (death, strokes, and HF-related unplanned hospitalizations) 
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at one, two, three, and fours years after the initial procedure was 97.6%, 97.6%, 97.6%, and 
88.7%. Among the HFpEF patients, one (1.8%) patient died due to cancer during the follow-up 
period. After 1.4 ± 0.5 procedures, 47 (85.5%) patients remained free from recurrent AF, and at 
one, two, three, and fours years after the last procedure was 90.0%, 84.6%, 79.3%, and 79.3%. 
Four studies, including three systematic reviews and/or meta-analysis and one single 
study, aimed to compare catheter ablation to medical therapy in patients with AF and HFrEF 
alone. Specifically, AlTurki and et al. (2019) retrieved and summarized seven randomized 
controlled trials, enrolling 856 patients. The methodology was thorough, and the systematic 
literature review was performed according to the PRISMA statement. The search was limited to 
human studies in peer reviewed journals from inception to February 26, 2018. The authors hand 
searched and cross referenced retrieved publications, review articles, and guidelines to ensure the 
inclusion of all relevant studies. For each randomized control trial, two reviewers independently 
reviewed the literature, and disagreements were resolved by consensus. The analysis of the study 
concluded that compared with medical therapy, AF catheter ablation was associated with a 
significant reduction in mortality (risk ratio 0.50; 95% CI 0.34 to 0.74; p=0.0005).  Limitations 
of the study included the absence of clinical trials with long term clinical outcome assessment 
comparing catheter ablation with a pure rate control strategy, such as excluding amiodarone use 
completely. As well, the number of included studies and sample size is relatively small, 
preventing an effective analysis of publication bias and questions the generalizability of the 
study results. Comparably to AlTurki and associates (2019), Smer et al. (2018) determined that 
ablation of AF was associated with less HF-related death from any cause in patients with HFrEF 
(95% CI 0.34-0.74, p=0.0005; OR 0.46, CI 0.29‐0.73, p=0.0009, respectively).  
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There were two studies captured that attempted to determine the relationship between 
catheter ablation and medical therapy in terms of mortality rates, however demonstrated weak 
evidence. The systematic and meta-analysis study by Ruzieh et al. (2019) results showed all-
cause mortality was significantly lower in the catheter ablation group (OR 0.49; 95% CI 0.31 – 
0.77; p=0.002).  However, the trials were not designed or powered to detect a mortality 
difference, and thus the confidence in the outcome estimate derived from pooled data is low. 
Additionally, the retrospective cohort study by Geng et al. (2017) aimed to determine the 
associated adverse events of catheter ablation of AF in patients with HF compared to rate control 
medical strategies, including BBs and/or digoxin. The study found that all-cause mortality was 
higher in the rate control group compared to the catheter ablation group (7.9% vs. 3.3%, 
p=0.126), however the results were not deemed statistically significant. 
Three studies, including one meta-analysis and two single studies, discussed the 
outcomes of medical therapy when treating patients with combined AF and HF. In particular, a 
meta-analysis by Xu et al. (2019) identified 12 studies, including six post-hoc analysis of 
randomized control trials and six observational studies, capturing data from a total of 38,133 
patients. The aim was to investigate the effects of BBs on outcomes in patients with chronic HF 
and AF. Although BBs were associated with significant decrease in all-cause mortality for 
patients with combined AF and HF (95% CI 0.65-0.82, p<0.001), the analysis demonstrated that 
treatment with BBs was not associated with a reduction of cardiovascular mortality (RR: 0.83; 
95% CI 0.65 –1.06, p=0.14). Although the study does not specifically compare medical therapy 
to catheter ablation, the analysis demonstrates that BBs are not the most optimal treatment 
strategy for the subpopulation of interest. Similarly, a retrospective observational study by Yu et 
al. (2018) assessed the efficacy of rate control medications in AF patients with HF. Patients were 
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identified with (n=2,441) or without (n=4,593) HF and assigned to a treatment group if they 
received one type of medication, including BBs, CCBs, or digoxin. In patients without HF, there 
was no significant difference in the risk of death among the medication subgroups. The risk of 
death was lower in patients receiving BBs (adjusted hazard ratio 0.75, 95% CI 0.64-0.88; 
p<0.001) and CCBs (adjusted HR 0.74, 95% CI 0.55-0.98; p=0.036) compared with those who 
did not receive rate control medications in the patients with AF. However, there was no 
significant difference between patients treated with digoxin or not being treated with rate control 
medication (adjusted hazard ratio 1.01, 0.86 – 1.19; p=0.928). Also, the use of BBs reduced the 
mortality rate for AF patients with HF, but not for those without HF. The analysis of the 
retrospective observational study by Machino-Ohtsuka et al. (2019) determined that maintaining 
sinus rhythm with catheter ablation and/or AADs compared to rate control medications, such as 
BBs, CCBs, and digoxin, was associated with lower occurrence of a composite endpoint of 
cardiovascular death or hospitalization for HF.  
In summary, the analysis for the majority of the forementioned studies demonstrate 
statistical significance in regards of ablation of AF in patient with HF and the association with 
decreased mortality compared to medical therapy. As well, three articles addressed and studied 
specific medications, determining that treatment with pharmacotherapy was not associated with a 
reduction of cardiovascular mortality compared to catheter ablation. As such, the results are 
robust enough to be clinically significant, and thus catheter ablation should be considered as an 
option in clinical practice for the management of concomitant AF and HF. 
QoL and Functional Capacity 
The literature captured in this review also explored the impact of interventions, including 
catheter ablation and pharmacotherapy of rhythm or rate control, on QoL and functional capacity 
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for patients with concomitant AF and HF. The analysis of the studies considerably demonstrate 
that catheter ablation is associated with improved QoL and functional capacity compared to 
pharmacotherapy in the management of patients with combined AF and HF. In particular, eight 
studies discussed management of combined AF and HF pertaining to QoL and functional 
capacity for individuals undergoing catheter ablation compared to pharmacotherapy, including 
seven systematic and/or meta-analyses (AlTurki et al., 2019; Chen et al., 2020; Ma et al., 2020; 
Ruzieh et al., 2019; Smer et al., 2018; Turagam et al., 2019; Zhu et al., 2016) and one single 
study (Kuck et al., 2019). There are various ways QoL and functional capacity can be evaluated, 
including 6-minute walk test distance, Minnesota Living with HF Questionnaire scores, and peak 
oxygen consumption – see table 3 below. 
Table 3  
QoL and Functional Capacity 







AlTurki et al. (2019) X X  
Chen et al. (2020)  X  
Ma et al. (2020) X  X 
Ruzieh et al. (2019) X X  
Smer et al. (2018) X X X 
Turagam et al. (2019) X  X 
Zhu et al. (2016)   X 
Five systematic reviews or meta-analyses determined catheter ablation of AF in HF 
patients significantly improved 6-minute walking test distances. Specifically, a meta-analysis by 
Ma et al. (2020) included seven studies involving 856 patients with a mean age ranged from 55 
to 64 years old. Baseline LVEF of all the patients was < 50% and NYHA class was II-IV in 
participants. All of the participants in the catheter ablation group underwent pulmonary vein 
isolation, most of who underwent additional linear and complex or fractionated electrograms 
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ablation. Medical rate control strategy was introduced to control group in four trials. The study 
was performed according to recommendations from the guidelines of the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses and Cochrane Handbook for Systematic 
Reviews of Interventions. The methodology was extensive, as two investigators independently 
searched the databases, including PubMed, Embase, and Cochrane Library enrolling patients 
with AF and HF who were assigned to catheter ablation, and medical rhythm or rate control 
groups. The studies included were published before February 27, 2018, and the language was 
restricted to English. Cochrane collaboration’s tool was used to assess risk of bias, as well as the 
quality of included studies. The items in the tool included random sequence generation, 
allocation concealment, blinding of participants and personnel, blinding of outcome assessment, 
incomplete outcome data, and selective reporting. Two reviewers independently extracted data 
from the included studies. 
The study aimed to evaluate the efficacy and safety of catheter ablation in patients with 
concomitant AF and HF, with the goal of creating a comprehensive representation of therapeutic 
strategies. The analysis of the study demonstrates catheter ablation had a longer 6-minute 
walking test (MD 26.67, 95% CI 12.07 to 41.27) than the medical rhythm or rate control group. 
Limitations of the study includes a lack of specified individual data to conduct subgroup analyses 
based on age, sex, and baseline diseases. As well, baseline LVEF was measured under AF 
rhythm in the included studies and echocardiography was used in 4 trials, thus there were 
relatively low accuracy and poor repeatability. Alike to Ma and colleagues (2020), the analysis 
of the studies by Turagam et al. (2019), AlTurki et al. (2019), Ruzieh et al. (2019), and Smer et 
al. (2018) also determined that catheter ablation was shown to be superior to conventional 
pharmacotherapy for improving 6-minute walking test (mean difference, 20.93 m [CI 5.91 to 
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35.95 m]; 30.15; 95% CI 10.47 to 49.84, p<0.0001; 29.3; 95% CI 11.8 – 46.8; p=0.001; 25.82, 
CI 5.46-46.18, p=0.01). 
Five systematic reviews and/or meta-analyses compared medical therapy and catheter 
ablation to determine the effect on Minnesota Living with HF Questionnaire (MLWHFQ) score 
in patients with combined AF and HF. In particular, AlTurki et al. (2019), assessed the efficacy 
and safety of catheter compared to medical therapy in patients with AF and HFrEF. The 
evaluation of the study results demonstrate that when compared with medical therapy, catheter 
ablation was associated with significant improvements in MLWHFQ score (95% CI –14.67 to 
− 4.38; p<0.0001) in the AF catheter ablation group compared to the medical therapy group. 
Alike to AlTurki and associates (2019), the analysis of the studies by Ruzieh et al. (2019), Ma et 
al. (2020), Chen et al. (2020), and Smer et al. (2018) determined that catheter ablation of AF in 
HF patients showed an improvement in MLWHFQ than the control group (mean difference -
12.1, 95% CI -20.9 to -3.3; p=0.007; -9.49, 95% CI -14.64 to − 4.34; 95% CI -15.7 to -2.5, 
p=0.007; -9.01, CI -15.56, -2.45, p=0.007). 
Lastly, four systematic reviews and/or meta-analyses compared medical therapy and 
catheter ablation to determine the effect on peak oxygen consumption in patients with combined 
AF and HF. Specifically, the systematic review of quantitative literature by Zhu et al. (2016) 
demonstrated significant evidence that when compared to a medical rate control strategy, 
catheter ablation of AF in HF patients significantly improves peak oxygen consumption (95% CI 
0.78-4.85, p=0.007). Similarly to Zhu and colleagues (2016), Turagam et al. (2019), Ma et al. 
(2020), and Smer et al. (2018) also determined catheter ablation was superior to conventional 
pharmacotherapy for improving peak oxygen consumption (mean difference, 3.17 mL/kg per 
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minute [CI 1.26 to 5.07 mL/kg per minute]; 3.16, 95% CI 1.09 to 5.23); 3.16, CI 1.04 to 5.29, 
p=0.004). 
In contrast to the above studies, a multicenter, open label, and randomized control trial by 
Kuck et al. (2019) attempted to determine the relationship between catheter ablation and medical 
therapy pertaining to QoL, however, there was an inconclusive effect. Specifically, there were no 
statistically significant differences between the ablation group and best medical therapy group in 
the secondary end points of change in 6-minute walking test (+46 m vs. +81 m, P=0.07) and 
QoL score (−11.2 vs. −8.9, p=0.42). The study was terminated due to ineffective study results. 
Although Kuck and colleagues (2019) demonstrated weak evidence, the prior mentioned studies 
associated catheter ablation in AF and HF patients with improved the 6-minute walking test, 
Minnesota Living with HF Questionnaire score, and peak oxygen consumption, and thus overall 
QoL and functional capacity in comparison to control strategies of medical therapy. Thus, 
ablation of AF in the HF population should be considered as a therapeutic option. 
LVEF 
The literature explored the impact of interventions, including catheter ablation and 
pharmacotherapy of rhythm or rate control, on LVEF for patients with concomitant AF and HF. 
Eight studies discussed management of combined AF and HF pertaining to LVEF for individuals 
undergoing catheter ablation compared to pharmacotherapy, including seven systematic and/or 
meta-analyses (AlTurki et al., 2019; Chen et al., 2020; Ma et al., 2020; Ruzieh et al., 2019; Smer 
et al.; 2018; Turagam et al., 2019; Zhu et al., 2016) and one single study (Kuck et al., 2019).  
Seven studies determined catheter ablation significantly increases LVEF in patients with 
combined AF and HF (AlTurki et al., 2019; Chen et al., 2020; Ma et al., 2020; Ruzieh et al., 
2019; Smer et al., 2018; Turagam et al., 2019; Zhu et al., 2016). In particular, a systematic 
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review of quantitative literature by Zhu et al. (2016) included three randomized controlled trials 
with a total of 143 patients, in which the quality was assessed by Cochrane Collaboration tool. 
The study was performed following the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses guidelines. The methodology was thorough, as the databases were systematically 
searched for articles until December 20, 2015. The references of the retrieved articles, relevant 
reviews, and previous meta-analyses, were manually searched for applicable citations. The data 
extraction and quality assessment were performed independently by two reviewers, and 
disagreements were resolved by consensus. The primary outcome in the study was the change in 
the LVEF after catheter ablation or medical rate control therapy relative to baseline. The analysis 
of the study demonstrated significant evidence that when compared to a medical rate control 
strategy, catheter ablation in AF and HF patients significantly improves the LVEF (95% CI 0.7-
11.74, p=0.03). Limitations involved the small number of studies included, as well as a relatively 
small sample size of participants. As well, follow-up lengths were short, with the longest being 
12 months, and thus may have been insufficient for complications and recurrences to occur. 
Thus, the analysis of the long-term results was underpowered. 
Alike to Zhu and associates (2016), systematic reviews and/or meta-analyses by Smer et 
al. (2018), Turagam et al. (2019), AlTurki et al. (2019), Ruzieh et al. (2019), Ma et al. (2020), 
and Chen et al. (2020) determined that compared to medical therapy, catheter ablation has 
significantly improved LVEF with the following results, mean difference 5.93, CI 3.59‐8.27, 
p<0.00001, I2 = 87%; 6.95% (CI 3.0% to 10.9%); 95% CI 3.71-11.26, p<0.0001; 6.8%, 95% CI 




Dissimilarly to the above studies, the randomized control trial by Kuck et al. (2019) did 
not reveal any benefit of catheter ablation in patients with AF and advanced HF. Specifically, at 
one year, LVEF increased in ablation patients to a similar extent as in best medical therapy 
patients. The increase in LVEF from baseline to one year was 8.8% (95% CI 5.8%–11.9%) in the 
ablation group and 7.3% (4.3%–10.3%, p=0.36) in the best medical therapy group, thus both 
groups improved similarly over one year. However, the study was terminated due to ineffective 
study results. Although Kuck et al. (2019) did not determine statistically significant evidence, the 
results of the other forementioned studies are all in agreeance that ablation of AF in HF patients 
increases LVEF. 
In summary, according to the majority of the study results addressed in this section of the 
literature review, ablation of AF in HF patients significantly reduces re-hospitalization rates, 
increases the maintenance rate of sinus rhythm, improves mortality rate, and improves QoL and 
functional capacity, as well as LVEF, for AF patients complicated with HF, with statistically and 
clinically significant evidence. As such, ablation of AF in the HF population is related to better 
prognosis, as well as improved key health outcomes, and thus should be considered an initial 
therapeutic treatment strategy. 
Safety Considerations 
 Safety emerged as an important consideration when managing patients with concomitant 
AF and HF. The literature around safety was centred on the application of common medical 
therapies, including catheter ablation and pharmacotherapy. In total, five systematic reviews and 
three single studies discussed the safety considerations of the diverse therapies for use in the 
desired population. The main findings that will be further described below includes low 
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complications rates of catheter ablation, as well as the comparison between the safety of catheter 
ablation to medical therapy. 
Low Complication Rates of Catheter Ablation 
Complication rates of catheter ablation are important when considering management for 
concomitant AF and HF and were a prominent feature of the included literature. In the literature 
review, four studies demonstrated that there were low complication rates associated with catheter 
ablation (AlTurki et al., 2019; Black-Maier et al., 2018; Ma et al., 2020; Zhu et al., 2016). 
Specifically, a comprehensive review and meta-analysis by Zhu et al. (2016) explored the 
efficacy and safety of restoring the sinus rhythm using catheter ablation in patients with AF and 
HF. The study was performed following the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses guidelines, and all analyses were based on previous published studies. The 
data extraction and quality assessment were performed by two independent reviewers, and 
disagreements were resolved by consensus. Three randomized control trials with 143 patients 
were included, all of which had relatively low risks of bias, as the team followed a robust review 
process guided by Cochrane Collaboration tool. However, the studies included were relatively 
small with a short-term follow-up of 12 months, which may have been insufficient for 
complications to occur. As well, although the interventions did not permit blinding, the assessors 
of the follow-up data measurements were blinded. The analysis of the data revealed that although 
compared with medical therapy, catheter ablation of AF is associated with significant risks due 
to the nature of the invasive procedure, there was a relatively low complication rate observed in 
the ablation-treated patients. Of the analyzed studies included in the systematic review by Zhu 
and colleagues (2016), the procedural complication rates ranged from 7.7% to 15.4%. However, 
the study did not explicitly mention the types or severity of complication rates or adverse effects. 
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As such, the evaluation of the study demonstrated that catheter ablation is able to restore and 
maintain the sinus rhythms of AF and HF patients with a relatively low risk of complications and 
adverse effects, making the results clinically significant to the subpopulation of interest.  
Similarly to Zhu et al. (2016), the study by Ma et al. (2020) included seven randomized 
control trials enrolling 856 participants and aimed to evaluate the safety of catheter ablation in 
patients with concomitant AF and HF. The analysis of the study determined a relatively low 
procedural complication rate of catheter ablation at 6.4% (95% CI 2.7% to 10.1%), thus 
indicating ablation of AF was safe in HF patients. Additionally, the evaluation of a systematic 
review and meta-analysis of seven randomized control trials by AlTurki et al. (2019) showed that 
catheter ablation is a safe procedure in patients with AF and HFrEF, as the number of adverse 
events were relatively small, making this a feasible option for maintenance of sinus rhythm. 
Finally, an observational, retrospective cohort study by Black-Maier et al. (2018) discussed 
periprocedural adverse events for ablation of AF in HF patients, including access site bleeding 
(p=0.24), stroke or transient ischemic accident (p=0.177), or acute HF (p=0.396). However, the 
results were not statistically significant. Overall, when critically examining the studies to 
determine the complications rates of catheter ablation, low procedural adverse effects were 
found, and adverse events that did occur were not statistically significant. 
Safety of Catheter Ablation 
 The management of concomitant AF and HF is a challenging task, and thus determining 
the safety of catheter ablation compared to medical therapy helps guide treatment decisions. In 
the literature review, four studies compared safety of catheter ablation and pharmacotherapy for 
patients with concomitant AF and HF. The results of two studies demonstrated that when 
compared to medical therapy, catheter ablation has similar safety rates. Specifically, the stratified 
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pooled analysis of randomized data by Chen et al. (2020) compared rhythm control using AADs 
and rate control (Subset A), or rhythm control using catheter ablation vs. medical therapy (Subset 
B) in AF and HF patients. There were 11 randomized control trials with high methodological 
quality included for a total of 3,598 patients enrolled (Subset A: 2486; Subset B: 1112) with a 
mean age 67.0 ± 9.9 years, in which 78% were male patients. However, there were various small 
sample-size studies included in the pooled analysis. For the purpose of the literature review, 
Subset B is of interest, as it compares the safety of catheter ablation and medical therapy. The 
study was performed in accordance with the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses statement. Also, clinically relevant comparisons and stratified analysis were 
conducted for each subset group. The analysis of the findings demonstrate that catheter ablation 
is safe in patients with AF and HF, as they evaluated the safety of rhythm control strategies in 
patients with concomitant AF and HF. In this study, the authors compared catheter ablation 
rhythm control vs. medical therapy. The analysis of the findings included the rate of overall 
composite adverse events between the catheter ablation group and the medical therapy group, 
including death, stroke, major bleeding, cardiac arrest, intracranial haemorrhage, myocardial 
infarction, worsening HF, cardiac tamponade, pulmonary vein stenosis, and groin bleeding, were 
similar (22.8% vs. 34%, 95% CI 0.33–1.34, p=0.25). In terms of the catheter ablation-related 
adverse events, there were no procedure-related deaths, as the rate of tamponade during catheter 
ablation was 1.3%, the rate of groin complications was 1.3%, and the rate of pulmonary vein 
stenosis was 0.3%. Although there was a large sample size, based on the analysis of a total of 11 
studies with a combined 3598 patients enrolled, some of the studies included did have a small 
sample size, possibly affecting the generalizability of the study.  
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Similar findings were identified in a multicenter, open-label, and randomized controlled 
trial by Kuck et al. (2019), which compared catheter ablation of AF and best medical therapy for 
patients with HF. The study results showed that 64 patients in the ablation-group (65.3%) and 56 
best medical therapy group patients (56.0%; p=0.19) experienced at least one serious adverse 
event. Although, the percentage of patients experiencing adverse effects when undergoing 
ablation of AF appears to be higher than in practice. Serious adverse events related to the 
ablation procedure, including atrioesophageal fistula leading to death [n=1], cardiogenic shock 
[n=1], pericardial tamponade [n=1], pleural effusion [n=1], suspected pericarditis [n=1], damage 
of ICD system [n=1], and vascular access complications [n=2]), were observed in six patients. 
There were no statistically significant differences between groups in the incidence (8.2% and 
8.0%,), type of death (p=0.26), or in the incidence of serious cardiac disorders (48% and 43%, 
p=0.57). The study was terminated early due to being ineffective, demonstrating weak evidence. 
Another two studies reported on the safety of catheter ablation of AF in HF patients 
compared to pharmacotherapy, however demonstrated weak evidence. In particular, the 
observational, retrospective cohort study by Geng et al. (2017) included 394 patients with AF 
and HF, where 90 patients had AF ablation and 304 received medical rate control therapy. The 
study was conducted in three tertiary hospitals from January 2015 to 2016. Prior to enrollment, 
all patients received catheter ablation or medical rate control treatment decided by experienced 
doctors. The study was performed according to the STROBE statement, as well as followed a 
registered protocol at Clinical trials.gov. There was a short-term follow up period of 13.5 ± 5.3 
months, and sixteen patients were lost to follow-up. The study demonstrated the greater safety 
profile of catheter ablation when compared to medical therapy, including BBs and/or digoxin. 
Specifically, in patients with HF, catheter ablation for AF was associated with a lower risk of 
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major adverse cardiac effects, as 29.3% patients in the rate control group had major adverse 
cardiac events, which was significantly higher than in catheter ablation group (13.3%, 95% CI 
0.32–0.82, p=0.005), however, the results were not deemed statistically significant, and thus the 
relationship of catheter ablation for the treatment of combined AF and HF was not clear. 
Additionally, a meta-analysis of randomized control trials by Turagam et al. (2019) demonstrated 
weak evidence, as the results were driven primarily by one clinical trial. Thus, there was possible 
patient selection bias in the ablation group, lack of patient-level data, open-label trial designs, 
and heterogeneous follow-up length among trials. The study demonstrated that serious adverse 
events were more common in the catheter ablation groups, which were 7.2% in the AF ablation 
group and 3.8% in the standard pharmacotherapy group observed in the pooled analysis, 
however, differences between groups were not statistically significant (7.2% vs. 3.8%; RR, 1.68 
[CI 0.58 to 4.85]).  
Overall, although there is a risk of complications with catheter ablation, the long term 
benefits of all-cause mortality, HF hospitalizations, and overall clinical outcomes must be 
considered in clinical decision making process (Turagam et al., 2019). However, although 
compelling, the findings of the included articles do not definitively suggest that catheter ablation 
is a safer than medical rate control therapy for the treatment of concomitant AF and HF. 
Differing Treatment for HFrEF and HFpEF 
HF comprises a wide range of patients, from those with HFpEF to those with a reduced 
HFrEF, and the proportion of patients with HFpEF ranges from 22% to 73%. AF is present in up 
to 50% of patients with HF regardless of the type of HF, and both are associated with several 
common predisposing risk factors and a shared pathophysiology (Ichijo et al., 2018). Thus, it is 
important to investigate the most optimal treatment strategy for these patients and to determine if 
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the type of HF is a factor in the management. There are evolving ways to evaluate cardiac 
function, and echocardiography is the most accessible method to evaluate LVEF (Ezekowitz et 
al., 2017). The difficulty of establishing a standardized treatment regimen for patients with AF 
and differing types of HF emerged as a key finding in the integrative literature review.  
The literature explored the impact of interventions on different types of HF. In particular, 
catheter ablation was heavily researched, as well as other modalities including pharmacotherapy, 
strict and lenient rate control, and dual-site right atrial pacing as adjunct therapy. In particular, 
five single studies addressed whether or not treatment strategies for patients diagnosed with AF 
and HF differ based on a reduced or preserved ejection fraction. Specifically, three studies in the 
literature review determined that treatment of HF in AF patients is not dependent on the type of 
HF (Black-Maier et al., 2018; Hess et al., 2020; Ichijo et al., 2018). In contrast, two studies 
determined that treatment of combined AF and HF is dependent on whether or not the ejection 
fraction is reduced or preserved (Eitel et al., 2019; Saskena et al., 2018).  
A total of 106 patients with HF were divided into two groups (51 with HFrEF and 55 
with HRpEF) between 2010 and 2015, and were enrolled into a retrospective non-randomized 
study by Ichijo et al. (2018). The mean age was 62 ± 10 years, and only 21% were females. The 
follow-up period was 32.4 ± 18.6 months, which is a longer than majority of studies selected in 
the literature review. As the study is a single center nature and there was a lack of randomization 
of participants, there may have been biases in selecting healthier patients who were more suitable 
candidates for an invasive procedure. The study aimed to determine the long term effects of 
ablation of AF in patients with HF. At three years, freedom of AF recurrence, HF-related 
hospitalizations, and composite endpoints of all-cause death, stroke, and HF-related 
hospitalizations were examined. For HFrEF, the results were 88.7%, 97.6%, and 97.6%. For 
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HFpEF patients, the results were 79.3%, 96.2%, and 91.8%. At the final follow-up, low dose 
AADs were prescribed in 17 (33.3%) HFrEF and 12 (21.8%) HFpEF patients, and sinus rhythm 
was maintained after AF ablation in the vast majority of the HF patients. Freedom from the 
composite endpoint was approximately 90% after AF ablation during four years of follow-up, 
regardless of HFpEF or HFrEF. 
Similar to Ichijo and colleagues (2018), the analysis of the study by Black-Maier et al. 
(2018) did not demonstrate significant differences between catheter ablation of AF for patients 
with HFrEF compared to HFpEF. There was no statistically significant differences in 
improvements in NYHA functional class (p=0.135), rates of AF recurrence (33.9% vs. 32.6%; 
p=0.848), repeat ablation (6.0% vs. 3.1%; p=0.364), 12-month all-cause hospitalization (26.3% 
vs. 32.0%; p=0.350), or cardiovascular hospitalization rates (21.1% vs. 22.7%; p=0.768) for 
either HF type. Thus, ablation of AF has similar effectiveness in patients with HF, regardless of 
presence of systolic dysfunction, as there were no significant differences in procedural types, 
arrhythmia-free recurrence, or functional improvements between patients with HFpEF and 
HFrEF. Moreover, an observational analysis by Hess et al. (2020) aimed to characterize heart 
rates achieved at discharge in a current cohort of patients admitted with HF and AF. The study 
demonstrated that compared with strict rate control (heart rate < 80 beats/min), lenient rate 
control (heart rate < 110 beats/min) was associated with higher risks of death (95% CI 1.11 to 
1.33, p<0.001), all-cause readmission (95% CI 1.03 to 1.15, p<0.002), and death or all cause 
readmission (95% CI 1.05 to 1.18, p<0.001) at 90 days. As the analysis suggests that an elevated 
heart rate is associated with adverse outcomes, the analysis of the study determined heart rate > 
80 beats/min were associated with adverse outcomes, irrespective of LVEF. Thus, HF with the 
presence or absence of reduced ejection fraction did not impact the magnitude of adverse effects.  
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In contrast to the above, a retrospective observational analysis by Saksena et al. (2018) 
discussed a different treatment strategy using dual-site right atrial pacing as adjunct therapy to 
standard AAD therapy, determining if it would permit rhythm control and improve HF in 
patients with AF. There was a total survival rate of 83.9% at three years and 72.6% at five years, 
and 47% at 10 years in the combined HFrEF and HFpEF population. However, superior survival 
rates occurred in patients with HFpEF compared to HFrEF at three, five, and 10 years (88.2 vs. 
79.6%, 81.9 vs. 63.1%, and 59.9 vs. 33.6%); p=0.036). The authors concluded that it is feasible 
to suggest very long term restoration of sinus rhythm or atrial paced rhythm in HF populations, 
specifically in patients with HFpEF. Limitations of the study include small sample size with 
strict inclusion criteria, which limits the generalizability of the study, as well as no control group 
for alternative packing sites. The strengths of the study include a long follow-up period of 
approximately 9.3 years, and the recommendations are supported by other evidence as 
demonstrated in their discussion. As such, the novel finding of combining AADs and biatrial 
resynchronization can improve survival for HFpEF more than survival for HFrEF on maximal 
medical therapy, but requires further investigation. 
Alike to Saksena et al (2018), Eitel and colleagues (2019) determined that differing 
treatment strategies according to type of HF will produce similarly desirable outcomes. The 
authors performed a multi-center German ablation registry aimed to assess ablation strategies in 
patients with AF and HF, specifically comparing outcomes in patients with HFpEF, HF with 
mid-range EF (HFmrEF), and HFrEF. Ablation strategies differed significantly between the 
groups. The majority of patients with HFpEF (83.4%) and HFmrEF (78.4%) underwent 
pulmonary vein isolation (PVI) and 48.9% of patients with HFrEF, of which 47.3% underwent 
ablation of the atrioventricular node. The evaluation of the study determined that there were no 
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significant differences in terms of symptoms or severe adverse events, such as myocardial 
infarction, stoke, or major bleeding, between the three groups. The study also found that there 
were no differences in hospitalizations for patients undergoing AV-node ablation compared to 
PVI during follow-up. Additionally, arrhythmia recurrences occurred in 47.9% of HFpEF, 36% 
in HFmrEF, and 39.8% in HFrEF with a P value of 0.036. Lastly, the mortality rate was 
significantly higher in the HFrEF group (10.4%) compared to HFpEF (2.5%) and HFmrEF 
(2.2%) with a P value <0.001.  
In summary, it is unclear whether or not treatment of AF differs according to the type of 
HF, as some analyses determined that therapy depends on the type of HF, and others 
demonstrated desirable outcomes irrespective of HF type. Specifically, ablation was deemed to 
be an important therapeutic option in the management of patients with HF combined with AF, 
regardless of the HF type. As well, the presence of HFrEF and HFpEF did not affect clinical 
outcomes when considering lenient or strict HF control. Dissimilarly, a report from a registry 
study demonstrated that AF ablation strategies differed in patients based on the type of HF with 
similar results. As well, when performing dual-site right atrial pacing as an adjunct therapy to 
AAD therapy, the outcomes are more favourable in HFpEF compared to HFrEF. Thus, the 
difficulty of establishing a standardized treatment regimen for patients with AF and differing 
types of HF requires further exploration, and recommendations and guidelines should clearly 
inform clinicians about the risks and benefits of therapeutic options for individual patients with 
concomitant AF and differing types of HF. 
Summary 
There are clinical guidelines pertaining to the management of AF and HF alone, however, 
there is more limited guidance regarding concomitant management of both diseases together. 
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The current available therapeutic options for AF in patients with HF are diverse and current 
guidelines do not provide a clear consensus regarding the best approach to management (Ruzieh 
et al., 2019). The next chapter will include a discussion that synthesizes the evidence and 
highlights gaps in the literature, as well as provides future recommendations for the concomitant 




CHAPTER IV: DISCUSSION 
The body of literature captured within the review is very diverse, making it difficult to 
determine finite conclusions for treatment strategies and practices for combined AF and HF. The 
chapter will consider the findings of the review and discuss the management of AF in HF 
patients within a primary care setting. The key findings will be presented, including exploring 
the benefits of catheter ablation compared to pharmacotherapy, the safety considerations in 
treatment strategies, as well as discordant evidence and guidelines. Subsequently, a summary of 
recommendations for practice, education, research, and policy will be provided, culminating with 
a review of the strengths and limitations of the integrative literature review. 
Catheter Ablation as an Alternative to Medical Therapy 
The evidence appraised in the literature review demonstrates that catheter ablation is a 
superior management strategy compared to pharmacotherapy, whether rate or rhythm control, for 
improving outcomes in patients with concomitant AF and HF. There is clear evidence that 
catheter ablation of AF is associated with improved QoL, functional capacity, and LVEF, as well 
as reduced morbidity, mortality, and hospitalizations, thereby reducing the financial burden on 
the healthcare system and improving patient outcomes. Fifteen studies addressed catheter 
ablation being superior to medical therapy, eight of which were systematic or meta-analyses 
(AlTurki et al., 2019; Chen et al., 2020; Ma et al., 2020; Ruzieh  et al., 2019; Smer et al., 2018; 
Turagam et al., 2019; Xu et al., 2019; Zhu et al., 2016), and seven of which were single studies 
(Di Biase et al., 2016; Fukui et al., 2020; Geng et al., 2017; Ichijo et al., 2018; Machino-Ohtsuka 
et al., 2019; Marrouche et al., 2018; Yu et al., 2018). The following subsection will discuss how 




Improved QoL and Functional Capacity 
Catheter ablation remains a highly specialized procedure, and common reasons for 
ablation include improving symptoms and QoL, maintenance of sinus rhythm, as well as a 
medication-free lifestyle (Riahi, 2016). A strategy of sinus rhythm maintenance should be aimed 
primarily at reduction of patient symptoms to improve QoL and reduce healthcare utilization 
(Andrade et al., 2020). As discovered within the literature review, catheter ablation has been 
shown to be significantly more efficacious at achieving long term sinus rhythm and freedom 
from AF than medial therapy (Phillips, 2016). 
Analyses of the various studies and systematic reviews within the literature review have 
demonstrated clinically important improvements in QoL and functional capacity associated with 
catheter ablation over pharmacological rate control or rhythm control strategies. In particular, 
many studies examined in the literature review demonstrated that catheter ablation significantly 
improves QoL and functional capacity, which can be evaluated based on 6-minute walking tests, 
Minnesota Living with HF Questionnaire scores, and peak oxygen consumption. Six studies 
demonstrated that catheter ablation improved QoL and functional capacity when compared to 
conventional medical therapy (AlTurki et al.., 2019; Chen et al., 2020; Ma et al., 2020; Ruzieh et 
al., 2019; Turagam et al., 2019; Zhu et al., 2016). As well, symptoms factor heavily on 
determining whether AF ablation is worthwhile, as QoL scores demonstrate improvement after 
ablation, which became evident in the literature review. As such, ablation of AF is accepted as an 
alternative to pharmacologic treatment to prevent recurrent AF in symptomatic patients with 
minimal or no left atrial enlargement. However, repeat ablations might be necessary, such as for 
those with longstanding persistent AF compared to paroxysmal AF (Darby, 2016).  
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Catheter ablation is an invasive procedure offered by specialists (Ezekowitz et al., 2017), 
and has become an increasingly frequent procedure performed by electrophysiologists worldwide 
(Darby, 2016). Consultation is the act of seeking advice for diagnosis and/or management from 
specialists, including cardiologists and electrophysiologists. It is a widely used practice, and with 
the increasing complexity of patients' illnesses, cardiology consultations have become more 
frequent (Marques et al., 2014). Unfortunately, despite the evidence, underutilization of referrals 
for ablation of AF in HF patients occur (Sinner et al., 2015). As such, PCPs must collaborate 
with electrophysiologists, cardiologists, and cardiac clinic NPs associated with the management 
of AF and HF in an appropriate timeframe for the most optimal success (Ezekowitz et al., 2017). 
Providing PCPs with the knowledge of appropriate and timely referrals and consultation would 
create better preparedness to work within the broader interdisciplinary team, which is necessary 
for the optimal management of combined AF and HF in outpatient settings. 
Reduced Healthcare Burden 
AF and HF frequently coexist and increase the risk of stroke, HF-related hospitalizations, 
and all-cause mortality, particularly recently after the clinical onset of AF (Verma et al., 2017). 
Catheter ablation has been shown to be significantly more efficacious at achieving long term 
sinus rhythm and freedom from AF than medial therapy (Phillips, 2016). Thus, when evaluating 
ablation of AF in HF patients over a lifetime, the main finding encompasses catheter ablation 
being an economically appealing alternative to medical therapy. Specifically, catheter ablation is 
considered cost-effective intervention for the treatment of AF, and the most determining 
variables are the impact on stroke and hospitalization rates (Barra & Fynn, 2015).   
Various studies were evaluated in the literature review and determined catheter ablation is 
a more effective strategy than medical therapy with outcomes of rehospitalizations, AF 
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recurrence, mortality rates, and LVEF. Seven systematic and/or meta-analyses and six single 
studies determined that catheter ablation of AF was associated with less HF hospital 
readmissions compared to medical therapy (AlTurki et al., 2019; Chen et al., 2020; Di Biase et 
al., 2016; Fukui et al., 2020; Ma et al., 2020; Geng et al., 2017; Ichijo et al., 2018; Machino-
Ohtsuka et al., 2019; Marrouche et al., 2018; Ruzieh et al., 2019; Smer et al., 2018; Turagam et 
al., 2019; Xu et al., 2019). Five systematic and/or meta-analysis studies and five single studies 
determined that catheter ablation of AF was associated with lower arrhythmia recurrences when 
compared to pharmacotherapy in HF patients (AlTurki et al., 2019; Chen et al., 2020; Di Biase et 
al., 2016; Fukui et al., 2020; Geng et al., 2017; Ichijo et al., 2018; Marrouche et al., 2018; Ma et 
al., 2020; Ruzieh et al., 2019; Smer et al., 2018). Seven systematic and/or meta-analyses and six 
single studies demonstrated that catheter ablation was associated with less deaths in patients with 
concomitant AF and HF (AlTurki et al., 2019; Chen et al.,2020; Di Biase et al., 2016; Geng et 
al., 2017; Ichijo et al., 2018; Machino-Ohtsuka et al., 2019; Marrouche et al., 2018; Ma et al., 
2020; Ruzieh et al., 2019; Smer et al., 2018; Turagam et al., 2019; Yu et al., 2018; Xu et al., 
2019). Lastly, seven systematic and/or meta-analyses studies determined catheter ablation 
significantly increases LVEF in patients with combined AF and HF (AlTurki et al., 2019; Chen 
et al., 2020; Ma et al., 2020; Ruzieh et al., 2019; Smer et al., 2018; Turagam et al., 2019; Zhu et 
al., 2016). 
The findings of the literature review are in alignment with the AF guidelines by Andrade 
et al. (2020), as catheter ablation is recommended as a reasonable alternative to pharmacologic 
rhythm or rate control therapy for patients with HF. The above recommendations are supported 
by the Canadian Cardiovascular Society (CCS, 2017) HF guidelines, as catheter ablation of AF is 
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considered a therapeutic strategy to achieve and maintain sinus rhythm if rhythm control is 
indicated and AAD therapy has failed, or the patient is unable to tolerate AAD therapy. 
NPs are highly trained and independent healthcare providers that work in collaboration 
with other members of the healthcare team to manage the healthcare needs of patients. There are 
several known benefits of NP-led care for chronic diseases, including AF and HF (Smigorowsky 
et al., 2017). NPs are able to perform stroke risk assessment, re-evaluate patients with increasing 
symptoms to adjust medication regimes, and arrange for interventions, such as cardioversion or 
cardiac electrophysiology. Both interventions are able to improve patient outcomes, as well as 
have a positive impact on the healthcare system, limiting emergency room visits and hospital 
admissions. As well, earlier appropriate management produces fewer devastating, costly 
complications of stroke and HF in AF patients (Smigorowsky et al., 2017). As such, PCPs, 
including NPs, should be aware of the evidence based research behind the available options for 
managing the combined diseases. NPs also have a responsibility to deliver effective education to 
patients to make informed decisions, and recognize that their knowledge, or lack there of, could 
impact their illness trajectory (Watts et al., 2009). Specifically, shared decision making that is 
facilitated by decision aids could help patients choose an option that is compatible with their 
values. With that, there is a decrease in patients remaining undecided, or who play a passive role 
in the decision-making process, as well as improvement in patient knowledge, decisional 
conflict, and patient-provider communication (Wieringa et al., 2019). 
Safety Considerations 
Pharmacologic rate and rhythm control are limited in the AF and HF population due to 
variable efficacy, intolerance, and adverse reactions (Sinner et al., 2015). Ablation for AF in 
patients with HF has resulted in a paradigm shift, as there is evidence to show superiority over 
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medical therapy (Sinner et al., 2015). A main finding obtained from the literature review 
includes low complication rates of catheter ablation in patients with concomitant AF and HF. 
Three systematic studies and one single study determined that there is evidence for low 
complication rates of catheter ablation (AlTurki et al., 2019; Black-Maier et al., 2018; Ma et al., 
2020; Zhu et al., 2016). As such, ablation of AF in the HF population is determined to be a safe 
procedure due to the limited number of adverse events, making catheter ablation a feasible 
option for maintenance of sinus rhythm (AlTurki et al., 2019). 
 The safety profile of most AADs, including amiodarone, is a concern as they may 
provoke HF decompensation and other adverse effects (Ezekowitz et al., 2017). When 
considering these medications, consulting with an electrophysiologist, or other relevant 
specialists, in their use is highly encouraged for improved patient outcomes (Ezekowitz et al., 
2017; McDonald et al., 2021). One systematic study and one single study in the literature review 
also determined that catheter ablation and medical therapy share similar safety profiles (Chen et 
al., 2020; Kuck et al., 2019). The CCS Guidelines for the Management of HF recommend the use 
of AAD therapy with concomitant AF to achieve and maintain sinus rhythm. However, if rhythm 
control is indicated, it should be restricted to amiodarone (Ezekowitz et al., 2017). Most AADs, 
including amiodarone, have significant concerns related to their safety profile, especially in 
HFrEF. Although they are effective at suppressing cardiac arrhythmias, they might also provoke 
HF decompensation and cause other adverse effects (Ezekowitz et al., 2017), including 
proarrhythmia and multiorgan toxicity (Black-Maier et al., 2018). As such, due to the limitations 
and safety profile of AAD medications, catheter ablation of AF is a reasonable alternative 
therapeutic option for treating patients with associated HF. 
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 Self‐care research and clinical efforts have been hindered by the perceptions of both 
patients and providers, with beliefs that pharmacological interventions are more effective than 
lifestyle change. Given the lack of emphasis on self‐care in the healthcare system today, most 
patients expect that PCPs hold the responsibility for their patients’ health (Riegel et al., 2017). 
Both PCPs and patients need to alter their expectations about their respective roles in the 
prevention for cardiovascular diseases. Patients are able to understand their risks and benefits of 
treatment for their cardiovascular disease and treatment, first by having knowledge of their 
health status and awareness. The “Know Your Numbers” campaign was designed to encourage 
patients to determine their risk for cardiovascular disease, including five risk factors of blood 
pressure, total cholesterol, high‐density lipoprotein cholesterol, blood glucose, and body mass 
index being the focus. The goal is for patients to determine whether any of these factors are 
abnormal, allowing them to monitor their cardiovascular health and be actively engaged in their 
treatment plan and the decision making process (Riegel et al., 2017).  
Discordant Evidence and Guidelines 
Within the literature review, there were inconsistent management strategies that were 
revealed for AF patients with HFrEF compared to HFpEF. The analyses of three studies in the 
literature review determined that treatment of HF in AF patients is not dependent on the type of 
HF (Black-Maier er al., 2018; Hess et al., 2020; Ichijo et al, 2018). Controversy, the evaluation 
of two other studies determined that the treatment of AF and HF differs based on whether or not 
the ejection fraction is reduced or preserved (Eitel et al., 2019; Saskena et al., 2018). Black-
Maier et al. (2018) underwent an observational, retrospective cohort study that determined there 
is no significant difference in the type or severity of EF when treating HFpEF or HFrEF patients 
with ablation of AF. Specifically, catheter ablation of AF significantly improves NYHA 
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functional class and Mayo AF-Specific Symptom Inventory in patients with HFpEF and HFrEF. 
In contrast, Eitel et al. (2019) underwent a multi-center ablation registry that compared various 
ablation strategies in patients with HFpEF, HFmrEF, and HFrEF. Although treatment strategies 
for concomitant AF and HF differed between patients and had similarly desirable outcomes, 
there is a lack of randomized control trials in the literature review to truly identify whether or not 
differing treatment strategies for HFrEF and HFpEF make a statistically and clinically significant 
difference in patient outcomes. Although AF is common in patients with HF, most of the 
available data are from patients with HFrEF, therefore evidence regarding HFpEF is less 
established (Sartipy et al., 2017). Thus, further contributing to the conflicting, and thus unclear, 
treatment recommendations for AF in the HF population. 
A challenge for managing patients with more than one morbidity, such as combined AF 
and HF, includes the presence of inadequate guidelines. Clinical practice guidelines often only 
provide recommendations for disease-specific conditions, however, they do not guide prescribers 
in managing patients with multiple comorbidities. The significant increase in medication options 
for AF and HF patients further complicates the situation, as PCPs need to carefully deliberate the 
suitability of each treatment option for a particular patient in terms of cost, effectiveness, and 
adverse effects. These challenges may lead to inappropriate prescribing for patients with chronic 
disease, leading to poor disease control. As the majority of patients with chronic diseases are 
elderly who are at high risk for adverse events of medical therapy, and AF and HF are problems 
in the aging population (Smigorowsky et al., 2017), the population needs more detailed and 
conclusive guidelines. Lastly, inappropriate prescribing for chronic diseases also has a 
significant economic impact due to increased hospitalization, number of outpatient visits and 
medical costs (Sellappands et al., 2015). Thus, the above mentioned all contribute to a major 
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concern in the delivery of healthcare, and guidelines that encompass the management of multiple 
diseases, including AF and HF, need to be further researched and developed to improve patient 
outcomes and reduce financial burdens on the healthcare system. 
AF and HF Guidelines 
Multiple studies in the literature review demonstrated that catheter ablation was more 
beneficial when compared to medical therapy for concomitant AF and HF. However, the 
Focused Update of the CCS Guidelines for the Management of Atrial Fibrillation by Andrade et 
al. (2018) did not add a new recommendation for catheter ablation of AF in HF patients, thus, 
they recommend catheter ablation as a second-line treatment. As well, in the updated guideline, 
the CCS/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of AF 
by Andrade et al. (2018), catheter ablation of AF is recommended as an alternative approach to 
pharmacologic therapy, thus continue to refrain from highlighting catheter ablation as first-line 
therapy for AF in HF patients. Additionally, from the CCS (2017) HF guidelines, catheter 
ablation of AF is considered as a therapeutic strategy to achieve and maintain sinus rhythm if 
rhythm control is indicated and AAD therapy has failed or the patient is unable to tolerate AAD 
therapy, however, they labeled it as a weak recommendation with low-quality evidence (CCS, 
2017). As well, the updated HF guidelines from the CCS and Canadian Heart Failure Society is 
limited to key pharmacologic therapies for patients with HFrEF and mention that the 
management of comorbidities, including AF, have been addressed in previous guideline updates, 
although they acknowledge that evidence is quickly evolving in many of these areas (McDonald 
et al., 2021). As such, there is an absence of guidance for managing HF in the presence of AF, as 
well as a lack of discussion concerning catheter ablation. Therefore, as AF ablations are 
becoming more widespread in HF patients, standardized procedures across healthcare systems 
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are important in order to improve overall quality of the treatment strategy in HF patients, which 
includes developing guidelines for the management of the combined diseases (Riahi, 2016). 
Recommendations  
 Recommendations for areas of improvement in the PCP role, including education and 
professional development, practice, and research, had been formulated from the results of the 
integrative literature review. It is certain that PCPs, including NPs, will have some of the greatest 
exposure to HF patients with AF in outpatient settings, thus, they are key stakeholders for 
implementing the recommended improvements for managing the concomitant diseases. 
Education and Professional Development 
The increase in life expectancy and advances in surgical and anesthetic techniques have 
allowed for surgical procedures to be performed in a broad population of patients, including 
those with advanced age and multiple comorbidities, including AF and HF (Marques et al., 
2014). Catheter ablation has become an increasingly frequent procedure performed in 
electrophysiology laboratories worldwide (Darby, 2016). Unfortunately, despite the evidence, 
underutilization of referrals for ablation of AF in HF patients occurs (Sinner et al., 2015). 
Although AAD therapy remains as the foundation of AF treatment, the role of AF ablation as a 
therapeutic option has been well established. However, ablation of AF is only performed in a 
small percentage of patients with AF (Tanner at al., 2011). 
Throughout the literature review, it was made evident that catheter ablation of AF in HF 
patients should be considered a therapeutic management strategy. Similarly to catheter ablation, 
there is clear evidence that proves implantable defibrillators reduce mortality in high risk 
patients, however are underutilized due to lack of provider knowledge (Bernier et al., 2017). 
Sinner at al. (2015) studied the geographical variation of catheter ablation procedures among 
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Medicare beneficiaries in the USA. Although the prevalence of AF was greatest in the major 
metropolitan areas of the East and West Coasts, catheter ablation rates were higher in areas 
where the prevalence of AF was relatively low. Thus, the low rate of catheter ablation referrals 
was likely due to the uncertainty about safety, effectiveness, and benefit of catheter ablation. As 
such, the lack of provider knowledge regarding catheter ablation leads to reduced referrals, and 
therefore underutilization of catheter ablation for AF and HF patients. 
New research and guidelines are frequently being created and updated regarding AF and 
HF. As such, to address the underutilization of catheter ablation, PCPs should participate in 
continuing education, as well as educate themselves on treating patients with combined AF and 
HF. In Canada, there are resources available to education oneself on chronic disease 
management pertaining to AF and HF diseases. For example, systematic studies from UpToDate, 
the CCS/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of AF 
(2020), as well as the Comprehensive Update of the CCS Guidelines for the Management of 
Heart Failure (2017) and the CCS/CHFS Heart Failure Guidelines Update: Defining A New 
Pharmacologic Standard Of Care For Heart Failure With Reduced Ejection Fraction (2021). 
However, due to the discordant and difficult to interpret guidelines, PCPs should be comfortable 
with local support opportunities, as well as how to access support when caring for patients with 
concomitant AF and HF where complex decision making is apparent. For example, the British 
Columbia (BC) Heart Failure Network makes accurate, relevant, and up-to-date information 
regarding HF available to health care professionals in BC. As well, Rapid Access to Consultative 
Expertise (RACE) program is a telephone service line that involves access to speciality services 
for general practitioners. PCPs are able to consult a cardiologist tor review their treatment plan 
89 
 
direction or reassurance is required to aid in their decision making. As such, cardiac clinics are 
able to provide ongoing support for primary care practice (BC Ministry of Health, 2015).  
NPs are competent in coaching patients to make and accomplish their goals, educating to 
make informed decisions, and promoting decision aids to allow for more active participation in 
their patient’s care and improved shared decision making (Jeon & Benavente, 2016). The NP 
role engages patients with chronic diseases to participate in their treatment plan by self-
managing their conditions. As such, PCPS with proper training, materials, and resources are able 
to do so more effectively. However, it is difficult for PCPs, especially in small practices with 
limited resources, to know where to find information that will help them provide effective self-
management strategies to their patients. There are a variety of web-based tools that exist and can 
be easily updated and disseminated to PCPs in various ways. For example, the Prevention and 
Chronic Care Program at Agency for Healthcare Research and Quality authorized the 
development of a searchable library of actionable, free resources to aid PCPs in coaching 
patients on self-management strategies, including motivational interviewing (LeRoy et al., 2014). 
As AF and HF management strategies have convoluted and limited guidance, PCPs must seek 
out the expertise of their colleagues. As well, they must partake in ongoing educational courses 
and stay up to date with research and guidelines pertaining to the most optimal treatment 
strategies for the population of interest. 
Practice 
The management of concomitant AF and HF is a therapeutic challenge (Batul & 
Gopinathannair, 2017). By conducting the literature review from the perspective of a PCP, 
recommendations for practice became evident. There is uncertainty of AF’s independent role of 
HF in predicting the response to therapy, whether pharmacological therapy or catheter ablation 
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(Andrade et al., 2020). Even though guidelines for pharmacological therapy for HF is evident, 
there are various treatment modalities for AF, and as such there is no clear consensus on how to 
best to treat AF in the presence of HF (Verma et al., 2017). Based on the findings of the review, 
the main area for practice support revolves around the use of catheter ablation of AF in HF 
patients. There is also a need for a multidisciplinary approach for optimal management of 
concomitant AF and HF for improved patient outcomes. Also, as HF prevention among patients 
with AF involves identifying the patients at highest risk for the disease, self-management should 
be included in the treatment plan (Pandey et al., 2017).   
Catheter Ablation. The long term control of AF in HF patients has been significantly 
enhanced by catheter ablation of AF (Phillips, 2016). As a shorter interval of time between initial 
AF diagnosis and AF ablation is associated with an increased probability of procedural success, 
there is a need for early ablation for optimal outcomes (Chew et al., 2020a). As well, part of the 
mission to improve long term control of AF, or limit AF burden, should include the role of 
adjunctive interventions (Phillips, 2016).  
Catheter ablation is an evidenced based and established therapeutic option with 
reasonable safety and efficacy. However, success rates for persistent AF ablation are 
significantly lower than paroxysmal AF, despite a large spectrum of ablation strategies (Kocyigit 
et al., 2015). Individuals with paroxysmal AF have the highest success rates for AF ablation, 
whereas patients with long-standing persistent AF lasting more than three to five years have 
much lower success rates (Golian & Klein, 2021). The longer an individual has been in 
continuous AF, the less likely it is to terminate spontaneously, creating difficulties for restoring 
and maintaining sinus rhythm (Olshansky, 2019). As such, late referrals for ablation are 
associated with worse outcomes in patients with structural heart disease due to arrhythmia 
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recurrence and acute complications (Romero et al., 2018). A meta-analysis by Romero et al. 
(2018) demonstrated that early referral was associated with a statistically significant reduction in 
acute complications compared with the late referrals (CI 0.27 to 0.93; p=0.03). As well, 
paroxysmal AF has been shown to have increased annual elimination rates (approximately 75 to 
80%) than persistent AF (approximately 60 to 70%), and repeat ablations for AF result in higher 
effectiveness rates. These differing ablation success rates support the observation that the longer 
AF is present, the more the left atrium is altered to promote and perpetuate AF (Shapira, 2009).  
Although there is limited data on timing of catheter ablation of AF in HF patients, it is 
recognized that AF in a population with left ventricular systolic dysfunction should be regarded 
with relative urgency as not just a prognostic marker for poor outcomes, but as an effective 
treatment target prompting early referral (Phillips, 2016). As such, when catheter ablation is 
approached as a first-line strategy, it should generally be performed at an earlier stage of the 
disease for a significantly higher success rate and a decreased need for repeat procedures (Tanner 
et al., 2011). The collaboration between the referring PCP and cardiac specialists is essential, 
which includes appropriate and timely utilization of catheter ablation (Ezekowitz et al., 2017). 
Thus, educating PCPs, including NPs, regarding the appropriate timing of catheter ablation in the 
presence of AF and HF is necessary for the success of ablation and patient outcomes. Evidenced 
based research should be incorporated into education programs, including medical school and 
NP curriculum, that addresses the impact of AF and HF together as opposed to lone conditions. 
Collaboration. Consultation is the act of seeking advice for diagnosis and/or 
management. It is a widely used practice, and with the increasing complexity of patients' 
illnesses, cardiology consultations have become more frequent (Marques et al., 2014). PCPs act 
as gatekeepers to evidence-informed interventions, thus, their understanding of the challenge and 
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interaction of HF and AF could ensure that patients receive appropriate and timely treatment 
(Ezekowitz et al., 2017). As such, PCPs should collaborate with specialists to consider catheter 
ablation in an appropriate timeframe for the most optimal success (Ezekowitz et al., 2017).  
Adherence to Recommendations. The effectiveness of cardiology referrals involves 
many variables, including knowledge of medical management and effective communication 
between the consultant and PCP. The success primarily depends on adherence to suggestions 
provided by the cardiology team (Marques et al., 2014). Recommendations from cardiologists 
involves complex and aggressive treatments, thus the recommendations from cardiologists may 
be ignored or denied by PCPs (Marques et al., 2014). Poor adherence to cardiology referral 
recommendations is associated with unfavorable clinical outcomes (Marques et al., 2014). 
Specifically, there is a 43% reduction in unfavorable outcomes, including clinical worsening or 
death, in patients in the adherence group (6.3% of events) compared with patients in the non-
adherence group (11.1% of events) (Marques et al., 2014). To improve the effectiveness of 
cardiology referrals, identifying the factors that are correlated with compliance to 
recommendations is necessary. Adherence depends on the presence of follow-up notes in the 
medical chart, verbal reinforcement of recommendations, the number of cardiology suggestions, 
as well as the patient's age. A successful cardiology consultation includes effective 
communication with referring PCPs. It is apparent that variables representing effective 
communication, including follow-up visits and verbal reinforcement, is the most important 
predictor of adherence (Marques et al., 2014). As such, a multidisciplinary approach is necessary 
for optimal management of concomitant AF and HF to reduce acute care utilization and mortality 
(Ezekowitz et al., 2017). There is a need to educate PCPs surrounding the importance of 
appropriate and timely referrals as well as educate specialists, including cardiologists and 
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electrophysiologists, on the importance of optimal communication strategies when providing a 
consultation to the referring PCP. 
Self-Management and Risk Factor Reduction. Patients that understand their current 
health status and their risk for future conditions are more capable of engaging in adequate self‐
care with improved outcomes (Reigel et al., 2017). Self‐care is defined as a decision‐making 
process that addresses the prevention and management of chronic illness, with a focus on self‐
care maintenance, monitoring, and management (Reigel et al., 2017). NPs are well positioned to 
provide education and promote self‐management to patients and their caregivers, as well as assist 
in navigating their care and the healthcare system to be more engaged in their own treatment plan 
(Watts et al., 2009). Implementation of self-management interventions can improve patients’ 
lifestyle with AF, as well as prevent physical, psychological, and social problems that negatively 
affect patients and their daily life. Crucial areas of focus for the subpopulation include medical 
management by adherence to the treatment strategy, as well as behaviour modification (Andrade 
et al., 2020). By targeting modifiable risk factors for AF and HF, including obesity and tobacco 
smoking, there is potential to significantly reduce individual risk of mortality and morbidity, and 
thus reduce the healthcare burden (Chatterjee et al., 2017). Particularly, timely follow up 
appointments should address adherence to medications, coagulation tests, blood pressure and 
heart rate monitoring, smoking cessation, alcohol abuse, diet, as well as techniques for stress 
reduction (Rakhshan et al., 2019). The target population is able to be properly managed by NPs 
within an outpatient setting, as they are competent in behavioral modification for chronically ill 
patients, including coaching patients to establish and accomplish their goals (Jeon & Benavente, 
2016).  Additionally, NPs are able to create linkages and refer patients to cardiac clinics to 




Catheter ablation has provided healthcare with major advances for managing patients 
with AF (Al-Khatib et al., 2020). The literature review has demonstrated significant evidence 
that benefits exists within the setting of the HF population, as ablation of AF reduces 
cardiovascular hospitalizations, AF recurrence, and mortality rates, as well as improves QoL and 
functional capacity, and LVEF. However, due to the discordant guidelines and conflicting 
research for managing AF and HF, PCPs and specialists do not have standardized protocols or 
guidelines to follow. There remains a need for updated AF and HF guidelines, in addition to 
combined guidelines as both diseases share common risk factors and frequently co-exist (CCS, 
2017). The patient experience should be considered and further explored when developing 
guidelines, as catheter ablation is an invasive procedure with risks (Kocyigit et al., 2015). 
Catheter Ablation. The therapeutic success of ablation is high for paroxysmal AF, 
however it may be suboptimal in persistent AF (Batul & Gopinathannair, 2017). In older 
individuals with significant atrial enlargement, left ventricular dysfunction, and comorbidities, 
AF ablation may be inappropriate, as many of these individuals are already in permanent AF at 
the time of referral (Verma et al., 2017). There is a lack of studies for appropriate timing of 
ablation of AF in HF patients. Although it has been shown that earlier ablation of AF is required 
to increase likelihood of success, further studies are required to explore implementation of earlier 
catheter AF ablation and patient outcomes (Chew et al., 2020a). As well, future research is 
needed to examine whether long term adjunctive AAD therapy can further improve the response 
rates and reduce recurrences of AF after catheter ablation in the HF population (Phillips, 2016). 
As catheter ablation is a specialized procedure, PCPs must be informed of the most up to date 
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and evidence based research to inform their referral practice, ensuring appropriate and timely 
consultations. 
Patient decision aids include interventions to be used independently by patients, before or 
after a clinical encounter. They are designed to increase patient knowledge and increase shared 
decision making without increasing encounter duration (Scali et al., 2019). PCPs are able to help 
patients navigate self-management interventions to significantly improve lifestyle for patients 
with AF (Andrade et al., 2020). Decision aids could be developed for patients with AF and HF to 
better educate patients on their treatment options, and to promote the active engagement of 
patients in the decision-making process (Wieringa et al., 2019). 
HFrEF and HFpEF. There are several knowledge gaps regarding the potential effect of 
cardiac structure and function on the likelihood of AF ablation success. For example, some 
studies have shown that the reduction in AF burden that results from AF ablation improves 
LVEF and HF symptoms in patients with reduced ejection fraction attributed to ischemic or 
nonischemic cardiomyopathy (Al-Khatib et al., 2020). However, it is uncertain whether similar 
benefits might be observed in patients with HFpEF (Al-Khatib et al., 2020). Specifically, 
ablation of AF may cause, or worsen, left atrial non-compliance, which may result in a reduction 
of blood flow as well as pulmonary hypertension, right ventricular dysfunction, tricuspid 
insufficiency, and right atrial enlargement (Al-Khatib et al., 2020). This is clinically important, 
as incident HF in stable patients with AF is more commonly HFpEF, and is associated with poor 
long term outcomes (Pandey et al., 2017). As majority of the available data for AF and HF are 
focused on HFrEF compared to HFpEF, there is a need for further research and literature around 
the differing types of HF in the AF population (Sartipy, Dahlstrom, Fu, & Lund, 2017). 
Specifically, further studies are needed to determine the role and safety profile of AF ablation in 
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patients with HFpEF (Al-Khatib et al., 2020). As well, retrospective and observational studies 
were included, and thus there is a need for randomized control trials to help determine a 
consensus for treatment of AF in the presence of HF with differing ejection fractions. 
 Patient Experiences. There are significant gaps in AF patient’s knowledge about their 
condition, as well as knowledge of the risks and benefits of the treatment they are currently 
taking for their AF despite their disease being treated for several years. Patients often wish for 
more information about their treatment options (Seaburg et al., 2014). Particularly, some older 
patients with AF may prefer less invasive treatment strategies, whereas others might choose 
catheter ablation with goals of maintaining an active lifestyle free of AF symptoms or in an 
attempt to avoid further medical therapy (Sinner et al., 2015). There is a need for further 
qualitative studies to explore the lived experiences of patients with AF and HF to assist with 
guiding therapeutic management strategies. As well, there is also a need for further research 
developed into resources available to PCPs for providing education to patients for managing 
concomitant AF and HF.  
Generic patient reported outcome measures, such as the SF-36 and EQ-5D 
questionnaires, have been developed with an advantage of allowing comparison of QoL in 
patients with different diseases. However, these tools are less sensitive to the effects of a single 
disease on QoL. Thus, with the growing burden of combined AF and HF, the relatively high cost 
of treatment, and the appreciation of QoL as a treatment objective, there has been substantial 
interest in the development of AF-specific patient reported outcome measures for use in both 
clinical research and routine practice (Kotecha et al., 2016). Specific patient-reported outcome 
measures should be developed and utilized in practice to help guide the approach to managing 




Policy development is required for guidelines around concomitant AF and HF that include 
the PCP, demonstrating care across the continuum and within the context of interdisciplinary 
care. For example, catheter ablation has emerged as an effective therapy in patients with 
coexistent AF and HF. However, the CCS/Canadian Heart Rhythm Society Comprehensive 
Guidelines for the Management of AF (2020), as well as the Comprehensive Update of the CCS 
Guidelines for the Management of Heart Failure (2017), have similar recommendations for 
catheter ablation of AF in HF patients. However, neither guideline emphasizes catheter ablation 
as first line therapy, despite significant beneficial evidence. Both guidelines only briefly mention 
the other disease and do not mention the role of the NP for managing patients with both disease, 
as well as neglect guidance for referral practices. 
As presented in the previous chapter, the findings of the integrative review strongly 
support the use of catheter ablation as a first line option for patients with concomitant AF and 
HF. However, there is a clear need for policy surrounding clearer guidelines for the treatment of 
the two diseases together. Due to the challenged nature of managing patients with more than one 
morbidity, such as concomitant AF and HF, clinical practice guidelines need to focus on 
providing recommendations for multiple diseases to help guide prescribers in prescribing for 
patients with multiple comorbidities. With the significant increase in medication options, the 
guidelines need to be diligent in advising prescribers to carefully deliberate the suitability of 
medications in terms of cost, effectiveness, and adverse effects (Sellappans et al., 2015). The 
goal is easier management of combined diseases, as well as increased confidence in PCPs 
prescribing medications for patients with more than one chronic disease. More advanced 
guidelines have the potential to significantly decrease hospitalization, number of outpatient 
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visits, and medical costs, thus reducing the economic burden on the healthcare system. As well, 
patients with chronic diseases often receive care from multiple practitioners and institutions, 
which requires a high level of coordination (Sellappans et al., 2015). There is a need for policy 
that strengthens shared care and interdisciplinary care to allow PCPs to be an instrumental part of 
the patient’s journey. 
Limitations 
The review of the literature on managing AF in HF patients has provided key insight and 
recommendations for education, practice, and research. A strength of the review include the 
development of a comprehensive literature search strategy, as well as the systematic process for 
extracting and analyzing the data. Specifically, the literature review contains multiple study 
designs, including systematic studies and meta-analysis, as well as retrospective, observational, 
multi-centered, and single-centered studies, which allowed for a comprehensive overview of the 
management of concomitant AF and HF, including identifying actionable recommendations that 
could be implemented to support improved patient and health system outcomes.  
Despite many strengths of the literature review, there are relevant limitations to consider. 
The literature obtained from the review was limited to quantitative studies, thus, the experiences 
of the patient are not well established. The lack of patient experiences poses a challenge to 
understand the full picture of HF and AF care, as there is a lack of patient perspective and 
preference. There is a need for the patient’s experience and perspective when considering 
treatment options. As well, other methodological considerations may impact the assessment of 
the evidence and the application into practice. For example, there was an overall lack of ability to 
randomize participants, and as the studies majorly did not employ randomizations, the results of 
all studies are limiting the potential generalizability to the population of interest. Another 
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limitation involves most of the available studies being retrospective. As there is an absence of 
prospective or randomized control studies to determine causality and as a result, completely 
evaluating the best management for the concomitant disorders is difficult. In addition, challenges 
emerged when reviewing the studies, as it was difficult to clearly identify the various methods of 
managing the combined diseases.  
Another notable limitation of the literature review included catheter ablation being the 
focal point of treatment strategies. Some studies mentioned the types of medical therapy, 
whether rate or rhythm control, however many combined both strategies into a conventional 
medical therapy without thorough explanation. As such, there is a lack of available evidence 
pertaining to the best medical therapy of AF in HF patients, and thus, a thorough comparison was 
not able to be completed. Additionally, none of the articles specifically focused on the primary 
care setting, or mentioned the NP as a primary care provider. Instead, majority of the studies 
referred to physicians and specialists, including cardiologists and electrophysiologists. As such, 
there is a lack of NP perspective when managing concomitant AF and HF. However, literature 
was discussed that captured the NP practice, including coaching and educating patients, as well 
as having a similar scope of practice to primary care physicians. Thus, the recommendations will 
apply to NP practice and assist PCPs to best manage AF in the HF population. 
Conclusion 
The combination of AF and HF has a worse prognosis than either of the conditions alone, 
thus determining effective therapies is of paramount importance (Batul & Gopinathannair, 2017). 
The burden of the diseases on the healthcare system is expected to increase in the future, as both 
disproportionately affect the older population. As such, there are associated considerable implied 
healthcare costs, as well as morbidity and mortality (Batul & Gopinathannair, 2017). 
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The research question that guided the integrative literature review is, “How can the NP 
best manage HF patients with AF in outpatient settings to help reduce the burden on the 
healthcare system?” In the review, a search of key search terms in various databases and applied 
eligibility criteria yielded a final cohort of 20 articles, including nine systematic reviews and/or 
meta-analyses and 12 single studies from dates 2015 to present. The review highlighted three key 
themes, including catheter ablation being superior to pharmacotherapy, safety considerations of 
catheter ablation, and discordant guidelines for managing patients with AF in the presence of HF. 
The review of the available evidence clearly supports the benefits of catheter ablation as 
an alternative to pharmacotherapy due to improved QoL and functional capacity, and LVEF, as 
well as reduced hospital readmissions, AF recurrence, and mortality in concomitant AF and HF.  
However, the AF and HF guidelines are contradictory, as they refrain from recommending 
catheter ablation as a first line strategy. Although catheter ablation for AF has resulted in a 
paradigm shift with evidence indicating superiority over medical therapy (Batul & 
Gopinathannair, 2017), underutilization of referrals for ablation of AF in HF patients remains 
evident (Sinner et al., 2015). Therefore, next steps include education to increase PCPs utilization 
of appropriate and timely cardiology consults and referrals in patients with concomitant AF and 
HF, as success rates for persistent AF ablation are significantly lower than paroxysmal AF, 
despite a large spectrum of ablation strategies (Kocyigit et al., 2015). There is also a need for 
policy development concerning conclusive guidelines around the treatment of the concomitant 
AF and HF, as there are inconsistent and conflicting management strategies found within the 
literature. The information found within the literature review is valuable to PCPs, including NPs, 
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Appendix A: Database Searches 
CINHAL (EBSCO) 
Search Search Term/Key Words Results 
1 MH Heart Failure 43,140 
2 AB heart failure OR chf OR congestive heart 
failure  
55,027  
3 S1 AND S2 36,738 
4 MH Atrial Fibrillation 25,542 
5 atrial fibrillation OR afib OR af 21,330 
6 S4 AND S5 13,178 
7 antiarrhythmic drugs OR rate control OR rhythm 
control 
33,148 
8 MH "Physicians, Family" OR MH "Family Nurse 
Practitioners" OR MH "Primary Health Care" OR 
MH "Family Practice" 
 
100,467 
9 MH "Readmission" OR MH "Hospitalization+" 117,477 
10 MH "Health Care Costs+" OR MH "Outcomes 
(Health Care)+" OR MH "Preventive Health 
Care+" 
806,999 
11 S7 OR S8 OR S9 OR S10 992,493 
12 S3 AND S6 AND S11 363 
COCHRANE (EBM) 
Search Search Term/Key Words Results 
1 heart failure or chf* or congestive heart failure 35006 
2 atrial fibrillation or afib* or af* 212614 
3 antiarrhythmic drugs or rate control or rhythm 
control or catheter ablation or physicians, family 
or family nurse practitioners or primary health 
care or family practice 
17097 
4 health care costs OR outcomes OR preventative 
health care OR readmission OR hospitalization 
290309 
5 1 and 2 and 3 and 4 311 
MEDLINE (Ovid) 
Search Search Term/Key Words Results 
1 heart failure or chf* or congestive heart failure 215272 
2 atrial fibrillation or afib* or af* 7477977 
3 antiarrhythmic drugs or rate control or rhythm 
control or catheter ablation or physicians, family 
or family nurse practitioners or primary health 
care or family practice 
212320 
4 health care costs OR outcomes OR preventative 
health care OR readmission OR hospitalization 
1246093 
5 1 and 2 and 3 and 4 703 
120 
 






















Databases searched: CINHAL (EBSCO) (n = 363),
COCHRANE (EBM) (n=311), MEDLINE (Ovid) (n=703)
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w
er
 i
n 
th
e 
ca
th
et
er
 a
bl
at
io
n
 
gr
ou
p
 (
O
R
 0
.4
9;
 9
5%
 
R
an
do
m
iz
at
io
n 
w
as
 p
er
fo
rm
ed
 
us
in
g 
ra
nd
o
m
 
nu
m
be
r 
ge
n
er
at
io
n 
in
 
al
l 
tr
ia
ls
. 
 S
im
il
ar
 
ba
se
li
ne
 
ch
ar
ac
te
ri
st
ic
s 
fo
r 
pa
ti
en
ts
 i
n 
th
e 
ab
la
ti
o
n 
an
d 
th
e 
co
nt
ro
l 
gr
ou
p
s.
 
P
at
ie
nt
s 
w
er
e 
no
t 
bl
in
de
d,
 
as
 n
on
e 
of
 t
he
 
tr
ia
ls
 h
ad
 a
 
sh
am
 a
rm
. 
 T
he
re
 w
er
e 
lo
w
 r
is
k
s 
of
 
se
le
ct
iv
e 
re
po
rt
in
g,
 
at
tr
it
io
n
 b
ia
s,
 
de
te
ct
io
n 
an
d
 
se
le
ct
io
n 
b
ia
s 
in
 a
ll
 t
ri
al
s.
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9.
  
 M
et
a-
A
na
ly
si
s 
of
 A
tr
ia
l 
F
ib
ri
ll
at
i
on
 
A
bl
at
io
n 
in
 
P
at
ie
nt
s 
w
it
h
 
S
ys
to
li
c 
H
ea
rt
 
F
ai
lu
re
. 
 
 C
ar
di
o
va
sc
ul
ar
 
T
he
ra
pe
ut
ic
s.
 
L
at
es
t 
se
ar
ch
 
da
te
: 
O
ct
o
be
r 
1,
 
20
18
. 
 S
ea
rc
h 
te
rm
s:
 
“a
tr
ia
l 
fi
br
il
la
ti
o
n”
, 
“c
at
h
et
er
 
ab
la
ti
on
”,
 
“p
ul
m
on
ar
y 
ve
no
us
 i
so
la
ti
o
n”
, 
“h
ea
rt
 f
ai
lu
re
”,
 
“l
ef
t 
ve
nt
ri
cu
la
r 
dy
sf
un
ct
io
n”
, 
“l
ow
 e
je
ct
io
n 
fr
ac
ti
on
”,
 
“f
un
ct
io
na
l 
ca
pa
ci
ty
”,
 “
Q
oL
”,
 
“s
tr
ok
e”
, 
“h
os
pi
ta
li
za
ti
o
n”
, 
“m
or
ta
li
ty
”,
 a
nd
 
“d
ea
th
”.
 
 T
he
 s
tu
dy
 
pr
ot
oc
ol
 w
as
 
dr
af
te
d 
by
 t
hr
ee
 
of
 t
he
 a
ut
ho
rs
 a
nd
 
re
vi
se
d 
by
 a
ll
 
co
au
th
or
s.
  
 T
w
o 
au
th
or
s 
in
de
pe
nd
en
tl
y
 
re
vi
ew
ed
 a
ll
 
ra
nd
o
m
iz
ed
 p
at
ie
nt
s 
w
it
h
 A
F
 a
nd
 s
ys
to
li
c 
H
F
 t
o 
ei
th
er
 c
at
h
et
er
 
ab
la
ti
on
, m
ed
ic
al
 
th
er
ap
y,
 o
r 
at
ri
ov
en
tr
ic
ul
ar
-n
od
e 
ab
la
ti
on
 w
it
h 
pa
ce
m
ak
er
 
im
pl
an
ta
ti
on
. 
C
I 
0.
31
 –
 0
.7
7;
 
p
=
0.
0
02
).
  
 S
ig
n
if
ic
an
tl
y 
m
or
e 
pa
ti
en
ts
 i
n 
th
e 
A
F
 
ab
la
ti
on
 g
ro
up
 w
er
e 
in
 
si
nu
s 
rh
yt
h
m
 a
t 
th
e 
en
d 
of
 t
ri
al
s 
(7
3.
7%
 v
s.
 
18
.3
%
, 9
5
%
 C
I 
10
.2
 –
 
11
1.
7;
 P
<
 0
.0
01
).
 T
o 
ac
hi
ev
e 
th
is
 h
ig
h 
su
cc
es
s 
ra
te
 f
ro
m
 A
F
 
ab
la
ti
on
, r
ep
ea
t 
in
te
rv
en
ti
o
n 
w
as
 
al
lo
w
ed
 i
n
 a
ll
 t
ri
al
s 
an
d
 
th
e 
pe
rc
en
ta
g
e 
o
f 
pa
ti
en
ts
 w
ho
 u
n
de
rw
en
t 
re
pe
at
 a
bl
at
io
n 
ra
ng
ed
 
fr
om
 1
9%
 t
o 
54
%
. 
 T
he
 r
at
e 
of
 H
F
- 
re
la
te
d 
ho
sp
it
al
iz
at
io
ns
 w
as
 
si
gn
if
ic
an
tl
y 
lo
w
er
 i
n 
th
e 
ab
la
ti
o
n 
gr
ou
p
 
(2
6.
7
%
 v
s.
 4
5.
1%
, 
95
%
 
C
I 
0.
29
 –
 0
.6
4;
 p
<
 
0.
0
01
).
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ar
ti
cl
es
 a
nd
 
ab
st
ra
ct
s 
fo
r 
in
cl
us
io
n.
  
 M
ea
n 
fo
ll
ow
-u
p 
ti
m
e 
of
 1
5.
2 
m
on
th
s.
 
S
m
er
, 
A
., 
S
al
ih
, 
M
., 
D
ar
ra
t,
 
Y
. H
., 
S
aa
di
, 
A
., 
G
ud
de
ti
, 
R
., 
M
ah
fo
od
 
H
ad
da
d,
 
T
., 
K
ab
ac
h,
 
A
., 
A
ya
n,
 
M
., 
S
au
ra
v,
 
A
., 
A
bu
is
sa
, 
H
., 
&
  
E
la
yi
, C
. 
S
. 
 20
18
. 
 
T
he
 a
im
 o
f 
th
e 
st
ud
y 
w
as
 
to
 c
om
pa
re
 
ca
th
et
er
 
ab
la
ti
o
n 
to
 
m
ed
ic
al
 
th
er
ap
y 
in
 
pa
ti
en
ts
 w
it
h 
A
F
 a
nd
 
H
F
rE
F
. 
S
ys
te
m
at
ic
 
re
vi
ew
. 
 P
er
fo
rm
ed
 
ac
co
rd
in
g 
to
 t
he
 
P
re
fe
rr
ed
 
R
ep
or
ti
ng
 I
te
m
s 
fo
r 
S
ys
te
m
at
ic
 
R
ev
ie
w
s 
an
d 
M
et
a‐
A
na
ly
se
s.
 
 S
ea
rc
he
d 
da
ta
ba
se
s:
 
P
ub
M
ed
, W
eb
 o
f 
S
ci
en
ce
, 
C
IN
A
H
L
, a
nd
 
C
oc
hr
an
e 
L
ib
ra
ry
 
da
ta
ba
se
s.
 
 D
at
es
: 
Ja
nu
ar
y 
19
66
 t
hr
ou
g
h 
F
eb
ru
ar
y
 2
01
8
 
 S
ea
rc
h 
te
rm
s:
 
“a
tr
ia
l 
fi
br
il
la
ti
o
n”
, 
S
ix
 t
ri
al
s 
w
it
h 
a 
to
ta
l 
of
 7
75
 p
at
ie
nt
s 
w
er
e 
in
cl
ud
ed
. 
 T
he
 m
ea
n 
ag
e 
w
as
 
62
.2
 ±
 7
.8
 y
ea
rs
, 
m
os
tl
y
 m
al
es
 (
83
%
) 
w
it
h
 m
ea
n 
L
V
E
F
 o
f 
31
.2
 ±
 6
.7
%
.  
 In
cl
u
si
o
n 
C
ri
te
ri
a:
 
hi
st
or
y 
of
 A
F
 w
it
h 
a 
di
ag
no
si
s 
of
 H
F
; 
R
C
T
 t
o 
tr
ea
t 
A
F
 
w
it
h
 c
at
he
te
r 
ab
la
ti
on
 v
s.
 m
ed
ic
al
 
th
er
ap
y 
(r
at
e 
or
 
rh
yt
hm
 c
on
tr
ol
);
 
re
po
rt
ed
 m
ea
n 
di
ff
er
en
ce
s 
an
d/
or
 
nu
m
be
r 
of
 e
ve
nt
s 
fo
r 
L
V
E
F
, H
F
-r
el
at
ed
 
ho
sp
it
al
 a
dm
is
si
on
, 
6‐
m
in
ut
e 
w
al
k
 t
es
t 
di
st
an
ce
, a
nd
 o
ve
ra
ll
 
m
or
ta
li
ty
; 
ad
ul
t 
C
om
pa
re
d 
to
 m
ed
ic
al
 
th
er
ap
y,
 c
at
he
te
r 
ab
la
ti
on
 h
as
 
si
gn
if
ic
an
tl
y 
im
pr
ov
ed
 
L
V
E
F
 b
y
 5
.9
%
 (
M
ea
n 
di
ff
er
en
ce
 5
.9
3,
 C
I 
3.
5
9‐
8.
27
, 
p
<
 0
.0
00
01
, 
I2
 =
 8
7%
),
 
Q
oL
, (
m
ea
n 
di
ff
er
en
ce
 
−
9.
01
, C
I 
−
15
.5
6,
 
−
2.
45
, 
P
 =
 0
.0
07
, 
I2
 =
 4
7%
),
 a
nd
 f
un
ct
io
na
l 
ca
pa
ci
ty
 (
m
ea
n 
di
ff
er
en
ce
 2
5.
82
, C
I 
5.
4
6‐
46
.1
8
, 
p=
0.
01
).
 
 C
A
 h
as
 l
es
s 
H
F
 h
o
sp
it
al
 
re
ad
m
is
si
o
ns
 (
O
R
 0
.5
, 
C
I 
0.
32
‐0
.7
8,
 p
=
0.
00
2
).
 
 C
A
 h
as
 l
es
s 
H
F
 d
ea
th
 
fr
om
 a
ny
 c
au
se
 (
O
R
 
0.
4
6,
 C
I 
0.
29
‐0
.7
3,
 
p
=
0.
0
00
9)
. 
 
T
w
o 
au
th
or
s 
se
pa
ra
te
ly
 
se
ar
ch
ed
 t
he
 
da
ta
ba
se
s.
 
 T
he
 s
el
ec
te
d 
m
an
us
cr
ip
ts
 
an
d 
re
vi
ew
 
ar
ti
cl
es
 w
er
e 
m
an
ua
ll
y 
se
ar
ch
ed
 f
or
 
ad
di
ti
o
na
l 
st
ud
ie
s.
  
 T
it
le
s 
an
d 
ab
st
ra
ct
s 
w
er
e 
sc
re
en
ed
 t
o 
id
en
ti
fy
 s
tu
di
es
 
fo
r 
fu
ll
 t
ex
t 
re
vi
ew
. 
R
el
at
iv
el
y 
sm
al
l 
nu
m
be
r 
of
 p
at
ie
nt
s.
 
 S
ho
rt
er
 
fo
ll
ow
‐u
p 
du
ra
ti
on
 i
n 
th
e 
m
aj
o
ri
ty
 
of
 t
he
 
in
cl
ud
ed
 
st
ud
ie
s.
 
 S
el
ec
ti
on
 b
ia
s 
du
e 
to
 t
he
 
ty
pe
 o
f 
pa
ti
en
ts
 
of
fe
re
d 
to
 
pa
rt
ic
ip
at
e 
in
 
th
es
e 
R
C
T
s.
 
 C
A
 
pr
oc
ed
ur
es
 
w
er
e 
do
ne
 o
n 
or
al
 
an
ti
co
ag
ul
an
t
s,
 h
ow
ev
er
 n
o 
15
1
 
 M
et
a-
an
al
y
si
s 
of
 
ra
nd
o
m
iz
ed
 
co
nt
ro
ll
e
d 
tr
ia
ls
 
on
 a
tr
ia
l 
fi
b
ri
ll
at
io
n ab
la
ti
on
 
in
 
pa
ti
en
ts
 
w
it
h
 
he
ar
t 
fa
il
u
re
 
w
it
h
 
re
du
ce
d 
ej
ec
ti
on
 
fr
ac
ti
on
. 
 
 C
li
ni
ca
l 
C
ar
di
ol
o
gy
. 
“a
bl
at
io
n”
, a
nd
 
“h
ea
rt
 f
ai
lu
re
”.
 
 A
 t
w
o 
si
de
d 
P
 
va
lu
e 
of
 <
0.
0
5 
w
as
 c
on
si
de
re
d 
st
at
is
ti
ca
ll
y 
si
g
ni
fi
ca
nt
 f
o
r 
al
l 
an
al
ys
es
 
su
bj
ec
ts
 (
>
 1
8 
ye
ar
s 
of
 a
ge
).
 
 E
xc
lu
si
on
 C
ri
te
ri
a:
 
pu
bl
is
h
ed
 a
bs
tr
ac
t 
w
it
h
ou
t 
fu
ll
 t
ex
t 
pu
bl
ic
at
io
n;
 s
tu
di
es
 
as
se
ss
in
g 
th
e 
im
pa
ct
 
of
 c
at
he
te
r 
ab
la
ti
on
 
on
 A
F
 w
it
ho
ut
 
m
ed
ic
al
 t
re
at
m
en
t 
gr
ou
p;
 s
tu
di
es
 
la
ck
in
g 
en
dp
oi
nt
 
m
ea
su
re
s.
 
F
re
ed
om
 f
ro
m
 A
F
 w
as
 
hi
gh
er
 i
n 
p
at
ie
nt
s 
w
ho
 
ha
d
 c
at
he
te
r 
ab
la
ti
o
n 
(O
R
 2
4.
2,
 C
I 
6.
94
‐
84
.4
1,
 p
<
 0
.0
00
01
).
 
an
ti
co
ag
ul
an
t 
de
ta
il
s 
w
er
e 
av
ai
la
bl
e 
in
 
m
os
t 
st
ud
ie
s.
 
T
ur
ag
am
, M
. K
., 
G
ar
g,
 J
., 
W
ha
ng
, 
W
., 
S
ar
to
ri
, 
S
., 
K
or
ut
h,
 
J.
 S
., 
T
he
 a
im
 o
f 
th
e 
st
ud
y 
w
as
 
to
 c
om
pa
re
 
ca
th
et
er
 
ab
la
ti
o
n 
an
d 
ph
ar
m
ac
ot
h
er
ap
y 
in
 a
du
lt
 
pa
ti
en
ts
 w
it
h 
A
F
 a
nd
 H
F
, 
R
an
do
m
iz
ed
 
co
nt
ro
l 
tr
ia
ls
 t
ha
t 
co
m
pa
re
d 
cl
in
ic
al
 
ou
tc
om
es
 o
f 
ca
th
et
er
 a
bl
at
io
n 
ve
rs
us
 d
ru
g 
th
er
ap
y 
in
 a
du
lt
s 
w
it
h
 A
F
 a
nd
 H
F
 
O
ut
 o
f 
24
, 9
60
 
re
co
rd
s,
 a
 t
ot
al
 o
f 
6 
R
C
T
s 
m
et
 t
he
 
in
cl
us
io
n 
cr
it
er
ia
, 
an
d 
77
5 
pa
ti
en
ts
 
w
er
e 
in
cl
ud
ed
. 
 In
cl
u
si
o
n 
C
ri
te
ri
a:
 
R
C
T
s 
 p
ub
li
sh
ed
 i
n 
C
om
pa
re
d 
w
it
h 
d
ru
g 
th
er
ap
y,
 A
F
 a
bl
at
io
n 
re
du
ce
d 
al
l 
ca
us
e 
m
or
ta
li
ty
 (
9.
0%
 v
s.
 
17
.6
%
; 
ri
sk
 r
at
io
, 0
.5
2 
[9
5%
 C
I 
0.
33
 t
o 
0
.8
1]
) 
an
d 
H
F
 h
os
pi
ta
li
za
ti
on
s 
(1
6.
4
%
 v
s.
 2
7.
6%
; 
ri
sk
 
T
w
o 
in
ve
st
ig
at
or
s 
in
de
pe
nd
en
tl
y 
sc
re
en
ed
 a
ll
 
ti
tl
es
, e
xt
ra
ct
ed
 
da
ta
, a
nd
 
as
se
ss
ed
 s
tu
dy
 
qu
al
it
y.
 
 
T
he
 r
es
ul
ts
 
w
er
e 
pr
ed
om
in
at
el
y 
fr
om
 1
 
cl
in
ic
al
 t
ri
al
. 
 P
os
si
b
le
 
pa
ti
en
t 
se
le
ct
io
n 
b
ia
s 
15
2
 
 M
il
le
r,
 
M
. A
., 
L
an
ga
n,
 
N
., 
S
of
i,
  
A
., 
G
om
es
, 
A
., 
C
ho
ud
ry
, 
S
., 
D
uk
ki
pa
t
i,
 S
. R
., 
&
 
R
ed
dy
, 
V
. Y
. 
 
 20
19
. 
 
 C
at
he
te
r 
ab
la
ti
on
 
of
 a
tr
ia
l 
fi
b
ri
ll
at
io
n 
in
 
pa
ti
en
ts
 
w
it
h
 
he
ar
t 
fa
il
u
re
. 
 
 A
nn
al
s 
of
 
In
te
rn
al
 
M
ed
ic
in
e
. 
 
to
 d
et
er
m
in
e 
th
e 
be
ne
fi
ts
 
an
d 
ha
rm
s.
 
 T
he
 q
ua
li
ty
 
of
 i
nd
iv
id
ua
l 
st
u
di
es
 w
er
e 
as
se
ss
ed
 
us
in
g 
th
e 
C
oc
hr
an
e 
R
is
k 
o
f 
B
ia
s 
T
oo
l.
 
w
er
e 
in
cl
ud
ed
 i
n 
th
e 
st
ud
y
. 
 D
at
a 
so
ur
ce
s:
 
C
li
ni
ca
lT
ri
al
s.
g
ov
, P
ub
M
ed
, W
eb
 o
f 
S
ci
en
ce
, E
B
S
C
O
 
In
fo
rm
at
io
n 
S
er
vi
ce
s,
 
C
oc
hr
an
e 
C
en
tr
al
 
R
eg
is
te
r 
of
 
C
on
tr
ol
le
d 
T
ri
al
s,
 
G
oo
gl
e 
S
ch
ol
ar
, 
an
d 
va
ri
ou
s 
sc
ie
nt
if
ic
 
co
nf
er
en
ce
 
se
ss
io
ns
. 
 D
at
a 
so
ur
ce
s 
w
er
e 
se
ar
ch
ed
 f
ro
m
 
Ja
nu
ar
y 
20
05
 t
o
 
O
ct
ob
er
 2
0
18
. 
 T
w
o 
in
ve
st
ig
at
or
s 
in
de
pe
nd
en
tl
y
 
pe
rf
or
m
ed
 
se
ar
ch
es
. 
 S
ea
rc
h 
te
rm
s:
 
“a
tr
ia
l 
fi
br
il
la
ti
o
n”
, 
“c
at
h
et
er
 
ab
la
ti
on
”,
 “
he
ar
t 
E
ng
li
sh
, a
 m
in
im
um
 
of
 6
 m
on
th
s 
of
 
fo
ll
ow
-u
p,
 
co
m
pa
ri
ng
 c
li
n
ic
al
 
ou
tc
om
es
 o
f 
ca
th
et
er
 
ab
la
ti
on
 a
nd
 d
ru
g 
th
er
ap
y 
in
 a
du
lt
s 
w
it
h
 A
F
 a
nd
 H
F
. 
ra
ti
o
, 0
.6
0
 [
C
I 
0.
39
 t
o 
0.
9
3]
).
  
 C
A
 o
f 
A
F
 i
m
pr
ov
ed
 
L
V
E
F
 (
m
ea
n 
di
ff
er
en
ce
, 6
.9
5%
 [
C
I 
3.
0
%
 t
o 
1
0.
9%
])
, 6
-
m
in
ut
e 
w
al
k 
te
st
 
di
st
an
ce
 (
m
ea
n 
di
ff
er
en
ce
, 2
0.
93
 m
 [
C
I 
5.
9
1 
to
 3
5.
9
5 
m
])
, p
ea
k 
ox
yg
en
 c
on
su
m
pt
io
n 
(V
O
2m
ax
) 
(m
ea
n 
di
ff
er
en
ce
, 3
.1
7 
m
L
/k
g 
pe
r 
m
in
ut
e 
[C
I 
1.
2
6 
to
 
5.
0
7 
m
L
/k
g 
pe
r 
m
in
ut
e]
),
 a
nd
 Q
oL
 
(m
ea
n 
di
ff
er
en
ce
 i
n 
M
in
ne
so
ta
 L
iv
in
g 
w
it
h 
H
ea
rt
 F
ai
lu
re
 
Q
ue
st
io
nn
ai
re
 s
co
re
, 
9.
0
2 
po
in
ts
 [
C
I 
19
.7
5 
to
 
1.
7
1 
po
in
ts
])
. 
 
 S
er
io
us
 a
dv
er
se
 e
ve
nt
s 
w
er
e 
m
or
e 
co
m
m
on
 i
n
 
th
e 
ca
th
et
er
 a
bl
at
io
n 
gr
ou
p
s,
 h
o
w
ev
er
 
di
ff
er
en
ce
s 
be
tw
ee
n 
gr
ou
p
s 
w
er
e 
no
t 
st
at
is
ti
ca
ll
y 
si
gn
if
ic
an
t 
(7
.2
%
 v
s.
 3
.8
%
; 
R
R
, 
1.
6
8 
[C
I 
0.
58
 t
o 
4
.8
5]
).
 
U
ti
li
za
ti
on
 o
f 
th
e 
C
oc
hr
an
e 
R
is
k
 o
f 
B
ia
s 
T
oo
l 
fo
r 
as
se
ss
in
g 
th
e 
st
ud
ie
s.
 
oc
cu
rr
ed
 i
n
 
th
e 
ca
th
et
er
 
ab
la
ti
on
 
gr
ou
p.
 
 L
ac
k 
of
 
pa
ti
en
t-
le
ve
l 
da
ta
. 
 O
pe
n
-l
ab
el
 
tr
ia
l 
de
si
gn
s.
 
 H
et
er
og
en
o
us
 
fo
ll
ow
-u
p 
le
ng
th
 a
m
on
g 
tr
ia
ls
. 
 N
o 
fu
nd
in
g 
w
as
 r
ec
ei
ve
 
fo
r 
th
e 
st
u
dy
. 
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il
ur
e”
, “
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ft
 
ve
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r 
ej
ec
ti
on
 f
ra
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io
n”
, 
“h
os
p
it
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iz
at
io
ns
”
, “
fu
nc
ti
o
na
l 
ca
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ci
ty
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 d
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 f
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at
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 r
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re
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w
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ab
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ra
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 b
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 p
at
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w
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 f
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 p
at
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 C
I 
0.
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at
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at
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 d
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 r
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C
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 f
o
r 
ra
nd
om
iz
ed
 
co
nt
ro
l 
tr
ia
ls
 
an
d 
th
e 
ri
sk
 o
f 
T
he
re
 w
as
 a
 
la
ck
 o
f 
in
di
vi
du
al
 
da
ta
 o
n 
pa
ti
en
ts
 i
n 
th
e 
st
ud
ie
s.
 
 P
os
t-
ho
c 
an
al
y
si
s 
of
 
R
C
T
s 
w
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at
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os
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